

## Independent Auditor's Report

### To the Members of Agilus Diagnostics Limited (formerly known as SRL Limited)

### Report on the Audit of the Standalone Financial Statements

#### Opinion

We have audited the standalone financial statements of Agilus Diagnostics Limited (formerly known as SRL Limited) (the "Company") which comprise the standalone balance sheet as at 31 March 2025, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, and its profit and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

#### Emphasis of Matters

- i. We draw attention to Note 55 and 56 of the standalone financial statements which deals with various matters including the ongoing investigation by Serious Fraud Investigation Office ("SFIO") on Fortis Healthcare Limited ("FHL" or the "Parent Company") and its subsidiaries (collectively referred to as "the Fortis Group") regarding alleged improper transactions and non-compliances with laws and regulations including Companies Act, 2013. These transactions and non-compliances relate to or originated prior to take over of control of Parent Company by its reconstituted board of directors in the year ended 31 March 2018. As mentioned in the note, the Group has been submitting information required by SFIO and is also cooperating in the regulatory investigations.

As explained in the said note, the Fortis Group had recorded significant adjustments/ provisions in its books of account during the year ended 31 March 2018. The Parent Company has launched legal proceedings and has also filed a complaint with the Economic Offences Wing ('EOW') against erstwhile promoters and their related entities based on the findings of the investigation conducted by the Fortis Group. Based on management's detailed analysis and consultation with external legal counsel, any further financial impact, to the extent it can be reliably estimated as at present, is not expected to be material.

Registered Office:

## Independent Auditor's Report (*Continued*)

### Agilus Diagnostics Limited (formerly known as SRL Limited)

- ii. We draw attention to Note 58 to the standalone financial statements describing the notices received by the Company from Anti-Corruption Branch, Government of National Capital Territory of Delhi and Central Bureau of Investigation, Anti-Corruption Branch, New Delhi in respect of alleged anomalies in diagnostic tests conducted in Aam Aadmi Mohalla Clinics. As also mentioned in the said note, the Company has recognised a provision of Rs. 1,660.57 lakhs against the trade receivables outstanding in books as at 31 March 2025. The Company is co-operating with the respective authorities in connection with the aforesaid notices and pending completion of the proceedings, the ultimate outcome of the matter and its consequential impact, if any, is currently not ascertainable on these standalone financial statements.

Our opinion is not modified in respect of these matters.

#### Management's and Board of Directors' Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit and other comprehensive loss, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

## Independent Auditor's Report (Continued)

### Agilus Diagnostics Limited (formerly known as SRL Limited)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- 2 A. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
  - c. The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.
  - d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.
  - e. On the basis of the written representations received from the directors as on 01 April 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.
  - f. the qualifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph (b) above on reporting under Section 143(3)(b) of the Act and paragraph [2B(f)] below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
  - g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate

**Independent Auditor's Report (Continued)**

**Agilus Diagnostics Limited (formerly known as SRL Limited)**

Report in "Annexure B".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- a. The Company has disclosed the impact of pending litigations as at 31 March 2025 on its financial position in its standalone financial statements - Refer Note 41, 55 to 59 to the standalone financial statements.
- b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- d (i) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 53(v) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (ii) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 53(vi) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.
- e. The final dividend paid by the Company during the year, in respect of the same declared for the previous year, is in accordance with Section 123 of the Act to the extent it applies to payment of dividend.

As stated in Note 54 to the standalone financial statements, the Board of Directors of the Company has proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with Section 123 of the Act to the extent it applies to declaration of dividend.

- f. Based on our examination which included test checks, except for the instances mentioned below, the Company has used accounting softwares for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective softwares:
  - i. The feature of recording audit trail (edit log) was not enabled at the application level for the accounting software used for maintaining the books of account relating to general ledger and other related records for certain fields and tables relating to areas such as revenue, inventory, procure to pay and property, plant and equipment.
  - ii. The feature of recording audit trail (edit log) facility was not enabled at the database level to log any direct data changes for the accounting softwares used for maintaining the books of accounts relating to revenue process and general ledger.

**Independent Auditor's Report (Continued)**

**Agilus Diagnostics Limited (formerly known as SRL Limited)**

Further, where audit trail (edit log) facility was enabled and operated throughout the year for the respective accounting softwares, we did not come across any instance of the audit trail feature being tampered with. Additionally, the audit trail has been preserved by the company as per the statutory requirements for record retention except for the period where audit trail was not enabled.

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022

RAHUL  
NAYAR

Digitally signed by  
RAHUL NAYAR  
Date: 2025.05.16  
23:33:18 +05'30'

**Rahul Nayar**

*Partner*

Place: Gurugram

Date: 16 May 2025

Membership No.: 508605

ICAI UDIN:25508605BMOLME2324

**Annexure A to the Independent Auditor’s Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025**

**(Referred to in paragraph 1 under ‘Report on Other Legal and Regulatory Requirements’ section of our report of even date)**

- (i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
- (B) The Company has maintained proper records showing full particulars of intangible assets.
- (i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, all items of property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company, except for the following which are not held in the name of the Company:

<b>Description of property</b>	<b>Gross carrying value (Rs. in lakhs)</b>	<b>Held in the name of</b>	<b>Whether promoter, director or their relative or employee</b>	<b>Period held- indicate range, where appropriate</b>	<b>Reason for not being held in the name of the Company. Also indicate if in dispute</b>
Subplot A of Plot no.1 bearing CTS No. 908 A admeasuring 1,078.10 sq. mtrs. situated in Village Pahadi, Goregaon West and CTNS No. 1395 A admeasuring 800.60 sq. mtrs. bearing Survey No. 52, Hissa No.	12,082.45	SRL Limited	No	26 March 2013	#

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

Description of property	Gross carrying value (Rs. in lakhs)	Held in the name of	Whether promoter, director or their relative or employee	Period held- indicate range, where appropriate	Reason for not being held in the name of the Company. Also indicate if in dispute
1 and Survey No. 53 (Part) situated in Village, Malad					

# The deed of conveyance of freehold land is in the name of SRL Limited, erstwhile name of the Company which was changed to Agilus Diagnostics Limited on 31 May 2023.

Fresh certificate of incorporation consequent upon change of name dated 31 May 2023 was issued by the Registrar of Companies, Chandigarh.

- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- (ii) (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks are in agreement with the books of account of the Company.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. The Company has granted unsecured loan to subsidiary company during the year in respect of which the requisite information, as applicable, is provided below. The Company has not made any investment in companies, firms and limited liability partnership during the year. However, the Company has made investments in mutual funds during the year.
- (a) Based on the audit procedures carried on by us and as per the information and explanations

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

given to us the Company has provided loans to subsidiary as below:

Particulars	Loans (Rs. in lakhs)
Aggregate amount during the year Subsidiary*	1,000.00
Balance outstanding as at balance sheet date Subsidiaries*	10,948.40

*\*As per the Companies Act, 2013*

- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the terms and conditions of the loans granted during the year are, prima facie, not prejudicial to the interest of the Company. The Company has not made any investment or provided any guarantee or security or advances in the nature of loans to any party during the year.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, in our opinion the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular except for the following loans given to Agilus Pathlabs Private Limited (formerly known as SRL Diagnostics Private Limited) (subsidiary):

Loan amount (Rs. in lakhs) as at 31 March 2025	Terms of repayment at the beginning of the year	Remarks
8,200	At the beginning of the year, Rs. 1,000 lakhs was repayable on demand before 31 March 2025 and balance amount of Rs. 7,200 lakhs was repayable on demand after 31 March 2025.	During the year, the terms have been extended to repayment on demand of INR 8,200 lakhs anytime after 31 March 2026. Further, there is no stipulation of payment of interest.
2,500	Repayable on or before 31 December 2025	No stipulation of payment of interest.

The Company has not given any advances in the nature of loans to any party during the year.

- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given to Agilus Pathlabs Private Limited (formerly known as SRL Diagnostics Private Limited) (subsidiary) as stated below, in our opinion the repayment of principal and payment of interest has not been stipulated and accordingly we are unable to comment on the amount overdue for more than ninety days:

**Annexure A to the Independent Auditor’s Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

Loan amount (Rs. in lakhs)	Terms of repayment at the beginning of the year	Remarks
8,200	INR 7,200 lakhs was repayable on demand anytime after 31 March 2025.	During the year, the terms have been extended for repayment on demand of INR 8,200 lakhs anytime after 31 March 2026.  Further, there is no stipulation of payment of interest.
2,500	Repayable on or before 31 December 2025	No stipulation of payment of interest.

Other than those mentioned above, there is no overdue amount for more than ninety days in respect of loans given. Further, the Company has not given any advances in the nature of loans to any party during the year.

- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion following instances of loans falling due during the year were renewed or extended or settled by fresh loans:

Name of the parties	Aggregate amount of loans or advances in the nature of loans granted during the year (Rs. in lakhs)	Aggregate overdue amount settled by renewal or extension or by fresh loans granted to same parties (Rs. in lakhs)	Percentage of the aggregate to the total loans or advances in the nature of loans granted during the year
Agilus Pathlabs Private Limited (formerly known as SRL Diagnostics Private Limited) (Subsidiary)	1,000.00	1,000.00	100%

- (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment except for the following loan to its related party as defined in Clause (76) of Section 2 of the Companies Act, 2013 (“the Act”):.

	Related Parties (Rs. in lakhs)
Aggregate of loan - Repayable on demand (A) - Agreement does not specify any terms or period of Repayment (B)	8,200 -

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

	<b>Related Parties (Rs. in lakhs)</b>
Total (A+B)	8,200
Percentage of loans to the total loans	75%

- (iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security as specified under Section 185 and 186 of the Companies Act, 2013 ("the Act"). In respect of loans granted and the investments made by the Company, in our opinion the provisions of Section 186 of the Act have been complied with.
- (v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.
- (vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of services provided by it and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.
- (vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have generally been regularly deposited by the Company with the appropriate authorities, though there have been slight delays in a few cases of Provident Fund, Income-Tax and Labour Welfare Fund.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable, except as mentioned below:

<b>Name of the statute</b>	<b>Nature of the dues</b>	<b>Amount (Rs. in lakhs)</b>	<b>Period to which the amount relates</b>	<b>Due date</b>	<b>Date of payment</b>
The Employees' Provident Funds and Miscellaneous Provisions Act, 1952	Provident fund	31.08	March 2019	15 April 2019	Not yet paid
The	Provident	27.07	April 2022 to	15th day of	Not yet

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Period to which the amount relates	Due date	Date of payment
Employees' Provident Funds and Miscellaneous Provisions Act, 1952	fund		August 2024	the following month	paid
Employees State Insurance Act, 1948	Employee State Insurance	2.98	April 2023 to August 2024	15th day of the following month	Not yet paid

- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Paid under protest (Rs. in lakhs)	Period to which the amount relates	Forum where dispute is pending
Income Tax Act, 1961	Disallowance of discounts given to collection centre.	158.20	-	AY 2006-07	Delhi High Court
Income Tax Act, 1961	Disallowance of discounts given to collection center and non deduction of TDS	1,256.14	-	AY 2007-08	Delhi High Court
Income Tax Act, 1961	Disallowance of discounts given to collection center, carry forward of unabsorbed depreciation	1,526.72	-	AY 2008-09	Delhi High Court
Income Tax Act, 1961	Deduction of TDS on discounts given to collection center.	988.80	-	AY 2008-09, 2009-10	Supreme Court
Income Tax Act, 1961	Disallowance of discounts given to collection center and	1,318.73	-	AY 2009-10	Delhi High Court

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Paid under protest (Rs. in lakhs)	Period to which the amount relates	Forum where dispute is pending
	interest expenditure under section 14A				
Income Tax Act, 1961	Disallowance of discounts given to collection centre.	738.44	-	AY 2010-11	Delhi High Court
Income Tax Act, 1961	Disallowance of discounts given to collection centre.	55.14	-	AY 2012-13	Income Tax Appellate Tribunal
Income Tax Act, 1961	Disallowance of discounts given to collection centre.	27.73	5.60	AY 2015-16	Commissioner of Income tax, (Appeals)
Income Tax Act, 1961	Disallowance of ESOP, legal and professional expenses and non-deduction of TDS	92.70	-	AY 2017-18	Commissioner of Income tax, (Appeals)
Income Tax Act, 1961	Disallowance of ESOP expense	172.09	-	AY 2018-19	Commissioner of Income tax, (Appeals)
Income Tax Act, 1961	Dispute with regard to tax deducted at source in different section.	111.36	20.17	AY 2017-18	Income Tax Appellate Tribunal
Income Tax Act, 1961	Dispute with regard to tax deducted at source in different section.	127.69	25.53	AY 2018-19	Commissioner of Income tax, (Appeals)
Finance Act 1994 read with service tax rules, 1994	Dispute with regard to nature of business.	965.91	33.16	July 2003- April 2006, October 2014- June 2017	Commissioner of service tax, Mumbai
Central Goods and	Dispute regarding GST input tax credit	161.67	7.70	July 2017 to March 2018	Office of the Special Commission

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Paid under protest (Rs. in lakhs)	Period to which the amount relates	Forum where dispute is pending
Services Tax Act, 2017 and State Goods and Services Tax, 2017					er Department of Trade & Taxes, Government of NCT of Delhi
Income Tax Act, 1961	Disallowance of ESOP expense, Gratuity and 14A	248.00	-	AY 2021-22	Commissioner of Income Tax, (Appeals)

- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.
- (ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- (c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.
- (e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries or joint venture as defined under the Act. Further, the Company does not hold any investment in associates.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries or joint venture (as defined under the Act). Further, the Company does not hold any investment in associates.
- (x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

- 3(x)(b) of the Order is not applicable.
- (xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.
- (xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit reports of the Company issued till date for the period under audit.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.
- (xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) According to the information and explanations provided to us, the Group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016) does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- (xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the

**Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022

RAHUL  
NAYAR

Digitally signed by  
RAHUL NAYAR  
Date: 2025.05.16  
23:33:37 +05'30'

**Rahul Nayar**

*Partner*

Place: Gurugram

Date: 16 May 2025

Membership No.: 508605

ICAI UDIN:25508605BMOLME2324

**Annexure B to the Independent Auditor's Report on the standalone financial statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025**

**Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act**

**(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)**

**Opinion**

We have audited the internal financial controls with reference to financial statements of Agilus Diagnostics Limited (formerly known as SRL Limited) ("the Company") as of 31 March 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2025, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

**Management's and Board of Directors' Responsibilities for Internal Financial Controls**

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

**Annexure B to the Independent Auditor's Report on the standalone financial statements of Agilus Diagnostics Limited (formerly known as SRL Limited) for the year ended 31 March 2025 (Continued)**

**Meaning of Internal Financial Controls with Reference to Financial Statements**

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Inherent Limitations of Internal Financial Controls with Reference to Financial Statements**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022

RAHUL  
NAYAR  Digitally signed by  
RAHUL NAYAR  
Date: 2025.05.16  
23:33:50 +05'30'

**Rahul Nayar**

*Partner*

Place: Gurugram

Date: 16 May 2025

Membership No.: 508605

ICAI UDIN:25508605BMOLME2324

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**STANDALONE BALANCE SHEET AS AT 31 MARCH 2025**

	Notes	As at	As at
		31 March 2025	31 March 2024
		(Rupees in Lakhs)	(Rupees in Lakhs)
<b>ASSETS</b>			
<b>Non-current assets</b>			
(a) Property, plant and equipment	4	23,684.72	23,749.27
(b) Capital work-in-progress	4	351.52	35.61
(c) Right-of-use assets	39	9,123.10	8,162.66
(d) Goodwill	5	9,234.50	9,234.50
(e) Other intangible assets	5	1,000.82	1,268.76
(f) Financial assets			
(i) Investments in subsidiaries	6	78,520.61	78,520.61
(ii) Investments in joint venture	6	150.00	150.00
(iii) Loans	7	8,200.00	9,700.00
(iv) Other financial assets	8	1,130.73	947.07
(g) Deferred tax assets (net)	9	4,052.98	3,748.85
(h) Other tax assets (net)	10	3,083.32	5,042.99
(i) Other non-current assets	11	279.70	595.02
<b>Total non-current assets</b>		<b>1,38,812.00</b>	<b>1,41,155.34</b>
<b>Current assets</b>			
(a) Inventories	12	2,868.33	2,858.45
(b) Financial assets			
(i) Trade receivables	13	13,171.63	11,903.94
(ii) Cash and cash equivalents	14	1,147.73	2,408.60
(iii) Bank balances other than (ii) above	15	7,087.82	3,138.14
(iv) Loans	16	3,535.26	2,069.68
(v) Other financial assets	17	208.46	1,996.03
(c) Other current assets	18	871.57	1,411.17
<b>Total current assets</b>		<b>28,890.80</b>	<b>25,786.01</b>
<b>Total assets</b>		<b>1,67,702.80</b>	<b>1,66,941.35</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity share capital	19	7,842.56	7,842.56
(b) Other equity		1,32,447.77	1,31,115.48
<b>Total equity</b>		<b>1,40,290.33</b>	<b>1,38,958.04</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	20	143.49	221.46
(ii) Lease liabilities	22	8,154.63	6,918.29
(b) Provisions	21	2,164.54	2,239.36
<b>Total non-current liabilities</b>		<b>10,462.66</b>	<b>9,379.11</b>
<b>Current liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	23	98.05	115.71
(ii) Lease liabilities	22	1,559.85	1,613.68
(iii) Trade payables	24		
- Total outstanding dues of micro enterprises and small enterprises; and		2,414.14	1,570.73
- Total outstanding dues of creditors other than micro enterprises and small enterprises		6,076.75	6,549.40
(iv) Other financial liabilities	25	4,388.21	6,126.42
(b) Other current liabilities	26	1,716.32	2,080.00
(c) Provisions	27	696.49	548.26
<b>Total current liabilities</b>		<b>16,949.81</b>	<b>18,604.20</b>
<b>Total liabilities</b>		<b>27,412.47</b>	<b>27,983.31</b>
<b>Total equity and liabilities</b>		<b>1,67,702.80</b>	<b>1,66,941.35</b>

See accompanying notes forming integral part of the standalone financial statements

1-60

In terms of our report attached

For **B S R & Co. LLP**  
Chartered Accountants

ICAI Firm's Registration No.:101248W/W-100022

RAHUL NAYAR Digitally signed by RAHUL NAYAR  
Date: 2025.05.16 23:24:11 +05'30'

**Rahul Nayar**  
Partner  
Membership Number: 508605

Place : Gurugram  
Date : 16 May 2025

For and on behalf of the Board of Directors of  
**Agilus Diagnostics Limited**  
(Formerly known as SRL Limited)

ASHUTOSH RAGHUVANSHI Digitally signed by ASHUTOSH RAGHUVANSHI  
Date: 2025.05.16 21:45:21 +05'30'

**Dr. Ashutosh Raghuvanshi**  
Director  
DIN:02775637

ANAND KUPPUSWAMY Digitally signed by ANAND KUPPUSWAMY  
Date: 2025.05.16 21:40:25 +05'30'

**Anand K**  
Managing Director & Chief  
Executive Officer

AKSHAY KUMAR TIWARI Digitally signed by AKSHAY KUMAR TIWARI  
Date: 2025.05.16 21:34:23 +05'30'

**Akshay Kumar Tiwari**  
Chief Financial Officer

DIN:02427196

SATYENDRA CHAUHAN Digitally signed by SATYENDRA CHAUHAN  
Date: 2025.05.16 21:59:09 +05'30'

**Satyendra Chauhan**  
Company Secretary  
Membership No. A14783

Place : Gurugram  
Date : 16 May 2025

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH 2025**

	Notes	Year ended 31 March 2025 (Rupees in Lakhs)	Year ended 31 March 2024 (Rupees in Lakhs)
<b>Income</b>			
(a) Revenue from operations	28	85,830.13	85,880.88
(b) Other income	29	3,309.36	4,284.43
<b>Total Income</b>		<b>89,139.49</b>	<b>90,165.31</b>
<b>Expenses</b>			
(a) Cost of materials consumed	30	21,818.19	22,155.82
(b) Cost of tests outsourced		4,161.25	3,058.61
(c) Employee benefits expense	31	19,226.61	20,323.31
(d) Finance costs	32	1,314.84	1,154.82
(e) Depreciation and amortisation expense	33	4,583.02	4,241.96
(f) Other expenses	34	34,655.40	34,625.41
<b>Total expenses</b>		<b>85,759.31</b>	<b>85,559.93</b>
<b>Profit before exceptional items and tax</b>		<b>3,380.18</b>	<b>4,605.38</b>
Exceptional items	35	-	(50.00)
<b>Profit before tax</b>		<b>3,380.18</b>	<b>4,655.38</b>
<b>Tax expense</b>			
(a) Current tax	36	966.46	1,218.17
(b) Deferred tax credit	36	(288.99)	(480.46)
<b>Total tax expense</b>		<b>677.47</b>	<b>737.71</b>
<b>Profit for the year</b>		<b>2,702.71</b>	<b>3,917.67</b>
<b>Other comprehensive income</b>			
Items that will not be reclassified to profit or loss			
(a) Remeasurements of the defined benefit liabilities	42	(60.17)	(29.14)
(b) Income tax relating to items that will not be reclassified to profit or loss	36	15.14	7.33
<b>Total other comprehensive loss (net of income tax) (a+b)</b>		<b>(45.03)</b>	<b>(21.81)</b>
<b>Total comprehensive income for the year</b>		<b>2,657.68</b>	<b>3,895.86</b>
<b>Earnings per equity share (Face value of Rs. 10 each)</b>			
(a) Basic (in Rupees)	37	3.45	5.00
(b) Diluted (in Rupees)	37	3.42	4.96

**See accompanying notes forming integral part of the standalone financial statements**

1-60

In terms of our report attached

For **B S R & Co. LLP**  
Chartered Accountants  
ICAI Firm's Registration No.: 101248W/W-100022

RAHUL NAYAR Digitally signed by RAHUL NAYAR  
Date: 2025.05.16 23:25:46 +05'30'

**Rahul Nayar**  
Partner  
Membership Number: 508605

Place : Gurugram  
Date : 16 May 2025

For and on behalf of the Board of Directors of  
**Agilus Diagnostics Limited**  
(Formerly known as SRL Limited)

ASHUTOSH Digitally signed by ASHUTOSH  
RAGHUVANSHI  
Date: 2025.05.16 21:46:26  
+05'30'  
RAGHUVANSHI  
**Dr. Ashutosh Raghuvanshi**  
Director  
DIN: 02775637

AKSHAY Digitally signed  
by AKSHAY  
KUMAR TIWARI  
Date: 2025.05.16  
21:35:17 +05'30'  
KUMAR  
TIWARI

**Akshay Kumar Tiwari**  
Chief Financial Officer

Place : Gurugram  
Date : 16 May 2025

ANAND Digitally signed by  
ANAND  
KUPPUSWAMY  
Date: 2025.05.16  
21:40:49 +05'30'  
KUPPUSWAMY  
Y

**Anand K**  
Managing Director & Chief  
Executive Officer  
DIN: 02427196

SATYENDRA Digitally signed by  
SATYENDRA CHAUHAN  
Date: 2025.05.16  
22:00:12 +05'30'  
CHAUHAN

**Satyendra Chauhan**  
Company Secretary  
Membership No. A14783

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**STANDALONE STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2025**

A. Equity Share capital	Amount				Total other equity
Particulars	Amount	Reserves and surplus	Share options outstanding account **	Securities premium *	General reserve ****
Balance as at 1 April 2023	7,842.56				
Changes in share capital during the year	-				
Balance as at 31 March 2024	7,842.56				
Changes in share capital during the year	-				
Balance as at 31 March 2025	7,842.56				
<b>B. Other Equity attributable to equity holders</b>					
Particulars					
Balance at 1 April 2024	61,050.03	306.75	306.75	306.75	333.60
Profit for the year	2,702.71	-	-	-	-
Other comprehensive loss for the year, (net of income tax)	(45.03)	-	-	-	-
Total comprehensive income for the year	2,657.68	-	-	-	-
Dividend payment to shareholders (Refer note 54)	(1,325.39)	-	-	-	-
Balance at 31 March 2025	62,382.32	306.75	306.75	306.75	333.60
Balance at 1 April 2023	59,491.25	306.75	306.75	306.75	333.60
Profit for the year	3,917.67	-	-	-	-
Other comprehensive loss for the year, (net of income tax)	(21.81)	-	-	-	-
Total comprehensive income for the year	3,895.86	-	-	-	-
Dividend payment to shareholders (Refer note 54)	(2,337.08)	-	-	-	-
Balance at 31 March 2024	61,050.03	306.75	306.75	306.75	333.60
	1,31,115.48				
	2,702.71				
	(45.03)				
	2,657.68				
	(1,325.39)				
	1,32,447.77				
	1,29,556.70				
	3,917.67				
	(21.81)				
	3,895.86				
	(2,337.08)				
	1,31,115.48				

\* The unutilized accumulated excess of issue price over face value on issue of shares, This reserve is utilised in accordance with the provisions of the Companies Act, 2013.

\*\* The fair value of the equity settled share based payment transactions with employees is recognised in the Standalone Statement of Profit and Loss with corresponding credit to share options outstanding account.

\*\*\* Retained earnings are the accumulated profits earned by the Company till date.

\*\*\*\* Amount transferred on forfeiture of employee stock options.

See accompanying notes forming integral part of the standalone financial statements

In terms of our report attached

For **B S R & Co, LLP**  
Chartered Accountants  
ICAI Firm's Registration No.:101248W/W-100022

**RAHUL NAYAR**  
Partner  
Date: 2025.05.16 23:27:11 +0530

Membership Number: 508605

Place : Gurugram  
Date : 16 May 2025

For and on behalf of the Board of Directors of  
**Agilus Diagnostics Limited**  
(Formerly known as SRL Limited)

**ASHUTOSH RAGHUVANSHI**  
Director  
Date: 2025.05.16 21:47:07

**Dr. Ashutosh Raghuvanshi**  
Director  
DIN:02775637

**AKSHAY KUMAR TIWARI**  
Date: 2025.05.16 21:33:36

**Akshay Kumar Tiwari**  
Chief Financial Officer

Place : Gurugram  
Date : 16 May 2025

**ANAND KUPPUSWAMY**  
Digitally signed by ANAND KUPPUSWAMY  
Date: 2025.05.16 21:41:53 +0530

**Anand K**  
Managing Director & Chief Executive Officer  
DIN:02427196

**SATYENDRA CHAUHAN**  
Date: 2025.05.16 22:01:15 +0530

**Satyendra Chauhan**  
Company Secretary  
Membership No. A14783

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2025**

	Notes	Year ended 31 March 2025 (Rupees in Lakhs)	Year ended 31 March 2024 (Rupees in Lakhs)
<b>A. Cash flows from operating activities</b>			
<b>Profit before tax</b>		3,380.18	4,655.38
<b>Adjustment for:</b>			
Depreciation and amortisation expense	33	4,583.02	4,241.96
Exceptional items	35	-	(50.00)
Loss/(profit) on disposal of property, plant and equipment (net)	34	3.90	4.81
Unrealised foreign exchange (gain)	29	(2.51)	(12.85)
Loss allowance for deposits and advances	34	10.77	20.23
Loss allowance for trade receivables	34	1,197.24	2,635.07
Contingent consideration for lab acquisition	34	1,015.11	-
Gain on sale of investment	29	(25.42)	(38.11)
Gain on termination of leases	29	(141.73)	(26.43)
Dividend income	29	(1,325.28)	(2,395.51)
Liabilities/provisions no longer required written back	28	(432.65)	(139.39)
Finance costs	32	1,236.97	1,076.61
Interest income	29	(1,781.42)	(1,756.23)
<b>Operating profit before changes in assets and liabilities</b>		<b>7,718.18</b>	<b>8,215.54</b>
(Increase)/Decrease in inventories		(9.88)	1,576.31
(Increase) in trade receivables		(2,029.77)	(3,437.47)
Decrease/(Increase) in other financial and other assets		2,146.16	(1,903.67)
Increase/(Decrease) in trade payables		370.81	(1,500.30)
(Decrease)/Increase in provisions		(122.96)	132.21
(Decrease)/Increase in other financial and other liabilities		(589.06)	174.89
<b>Cash generated from operations</b>		<b>7,483.48</b>	<b>3,257.51</b>
Income tax refund / (paid) (net)		1,324.94	(3,210.61)
<b>Net cash generated from operating activities</b>		<b>8,808.42</b>	<b>46.90</b>
<b>B. Cash flows from investing activities</b>			
Interest received		1,396.30	877.76
Dividend income from equity instruments		1,325.28	2,395.51
Fixed deposits made during the year		(11,750.00)	(12,435.49)
Fixed deposits matured during the year		7,768.62	15,928.88
Proceeds from sale of current investment		9,924.93	11,187.55
Current investment made		(9,899.51)	(11,149.44)
Loan (given) / repayment received	7,16	-	550.00
Payment of purchase consideration in business combination		(2,742.75)	(6,744.09)
Payments for purchase of property, plant and equipment and intangible assets		(2,227.72)	(2,178.33)
Proceeds from disposal of property, plant and equipment		75.82	64.53
<b>Net cash used in investing activities</b>		<b>(6,129.03)</b>	<b>(1,503.12)</b>
<b>C. Cash flows from financing activities *</b>			
Proceeds from borrowings		53.57	233.25
Repayments of borrowings		(149.20)	(131.48)
Principal payment of lease liabilities		(1,611.96)	(1,653.83)
Interest paid on lease liabilities		(769.88)	(597.49)
Finance costs paid		(137.40)	(126.54)
Dividend paid		(1,325.39)	(2,337.08)
<b>Net cash used in financing activities</b>		<b>(3,940.26)</b>	<b>(4,613.17)</b>
<b>Net decrease in cash and cash equivalents [A+B+C]</b>		<b>(1,260.87)</b>	<b>(6,069.39)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	14	2,408.60	8,477.99
<b>Cash and cash equivalents at the end of the year</b>	14	<b>1,147.73</b>	<b>2,408.60</b>

**\* Changes in financial liabilities arising from financing activities**

Particulars	Borrowings (including interest accrued)	Lease liability
<b>As at 1 April 2023</b>	<b>237.03</b>	<b>5,077.64</b>
Addition during the year	233.25	4,535.60
Acquisitions (Refer note 46A to 46D)	-	778.44
Derecognition of lease liability	-	(205.88)
Interest cost	25.68	597.49
Payment of lease liabilities (including interest of Rs. 597.49 Lakhs)	-	(2,251.32)
Repayments of borrowings during the year	(131.48)	-
Finance cost paid	(24.68)	-
<b>As at 31 March 2024</b>	<b>339.80</b>	<b>8,531.97</b>
<b>As at 1 April 2024</b>	<b>339.80</b>	<b>8,531.97</b>
Addition during the year	53.57	4,415.77
Acquisitions	-	-
Derecognition of lease liability	-	(1,621.30)
Interest cost	23.82	769.88
Payment of lease liabilities (including interest of Rs. 769.88 Lakhs)	-	(2,381.84)
Repayments of borrowings during the year	(149.20)	-
Finance cost paid	(24.53)	-
<b>As at 31 March 2025</b>	<b>243.46</b>	<b>9,714.48</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2025**

**Notes:**

- 1 During the year, the Company paid Rs. 198.40 Lakhs (31 March 2024 Rs. 266.50 Lakhs) towards corporate social responsibility expenditure (refer note 43).
- 2 The statement of cash flows for operating activities has been prepared in accordance with the "Indirect Method" as set out in the Ind AS 7 "Statement of Cash Flows".

**See accompanying notes forming integral part of the standalone financial statements**

1-60

In terms of our report attached

For **B S R & Co. LLP**  
Chartered Accountants  
ICAI Firm's Registration No.:101248W/W-100022

**RAHUL NAYAR** Digitally signed by RAHUL NAYAR  
Date: 2025.05.16 23:28:53 +05'30'

**Rahul Nayar**  
Partner  
Membership Number: 508605

Place : Gurugram  
Date : 16 May 2025

For and on behalf of the Board of Directors of  
**Agilus Diagnostics Limited**  
(Formerly known as SRL Limited)

**ASHUTOSH** Digitally signed by  
ASHUTOSH RAGHUVANSHI  
Date: 2025.05.16 21:47:50  
+05'30'  
**RAGHUVANSHI**

**Dr. Ashutosh Raghuvanshi**  
Director  
DIN:02775637

**AKSHAY** Digitally signed by  
AKSHAY KUMAR TIWARI  
Date: 2025.05.16  
21:43:29 +05'30'  
**KUMAR TIWARI**

**Akshay Kumar Tiwari**  
Chief Financial Officer

Place : Gurugram  
Date : 16 May 2025

**ANAND** Digitally signed by ANAND  
KUPPUSWAMY  
Date: 2025.05.16 21:42:32  
+05'30'  
**KUPPUSWAMY**

**Anand K**  
Managing Director & Chief  
Executive Officer  
DIN:02427196

**SATYENDRA** Digitally signed by  
SATYENDRA  
CHAUHAN  
Date: 2025.05.16  
22:02:48 +05'30'  
**CHAUHAN**

**Satyendra Chauhan**  
Company Secretary  
Membership No. A14783

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

**Note 1. Corporate Information**

Agilus Diagnostics Limited (formerly known as SRL Limited) (“the Company” or “Agilus Diagnostics”), is a public limited Company incorporated in 1995. The registered office of the Company is situated at Fortis Hospital, Sector-62, Phase - VIII, Mohali - 160062, Punjab, India and the corporate office of the Company is situated at 306, Tower-A, 3rd Floor, Unitech Cyber Park, Sector-39 Gurugram- 122002, Haryana, India.

The Company manages and operates a network of clinical reference laboratories, to provide testing, diagnostics and prognostics monitoring/ screening tests services. The Company also provides laboratory support services for clinical research studies and diagnostics centers.

**Note 2. Material accounting policies**

This note provides a list of the material accounting policies adopted in the preparation of these Standalone Financial Statements (“standalone financial statements”). The accounting policies adopted are consistent with those of the previous financial year.

**(a) Basis of preparation**

*(i) Statement of compliance*

These standalone financial statements have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) as per the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, notified under section 133 of Companies Act, 2013, (‘Act’) and other relevant provisions of the Act. All the amounts included in the standalone financial statements are reported in lakhs of Indian Rupees and are rounded to two decimals, except per share data.

The standalone financial statements are approved for issue by the Company’s Board of Directors on 16 May 2025.

*(ii) Functional and presentation currency*

These financial statements are presented in Indian Rupees, which is also the Company’s functional currency. All amounts are in Indian Rupees lakhs except share data and per share data, unless otherwise stated.

*(iii) Historical cost convention*

The standalone financial statements have been prepared under the historical cost basis except for the following items, which are measured on an alternative basis on each reporting date.

<b>Item basis</b>	<b>Measurement</b>
Contingent consideration assumed in a business combination	Fair value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

**(b) Current/ Non-current classification**

Based on the time involved between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has identified twelve months as its operating cycle for determining current and non-current classification of assets and liabilities in the balance sheet.

**(c) Measurement of fair values**

A number of the accounting policies and disclosures require measurement of fair values, for both financial and non-financial assets and liabilities. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company has an established control framework with respect to the measurement of fair values. This includes a finance team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values.

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

**(d) Business combinations**

Business combinations (other than business combinations between common control entities) are accounted for using the purchase (acquisition) method. The cost of an acquisition is measured as the fair value of the consideration transferred, equity instruments issued and liabilities incurred or assumed at the date of exchange. The consideration transferred does not include amounts related to the settlement of pre-existing relationships with the acquiree. Such amounts are generally recognised in the statement of profit and loss.

The cost of acquisition also includes the fair value of any contingent consideration. Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not remeasured and settlement is accounted for within equity. Otherwise, other contingent consideration is remeasured at fair value at each reporting date and subsequent changes in the fair value of the contingent consideration are recognised in the statement of profit and loss.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at fair value at the date of acquisition. Transaction costs incurred in connection with a business combination are expensed as incurred. The excess of the consideration transferred over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

the net identifiable assets of the business acquired, the difference is recognised in other comprehensive income and accumulated in equity as capital reserve provided there is clear evidence of the underlying reasons for classifying the business combination as a bargain purchase.

If the business combination is achieved in stages, any previously held equity interest in the acquiree is re-measured at its acquisition date fair value and the resulting gain or loss, if any, is recognised in profit and loss or OCI, as appropriate.

Business combinations arising from transfers of interests in entities that are under the control of the shareholder that controls the Company are accounted for as if the acquisition had occurred at the beginning of the earliest comparative period presented or, if later, at the date that common control was established; for this purpose comparatives are revised. The assets and liabilities acquired are recognized at their carrying amounts. The identity of the reserves is preserved, and they appear in the financial statements of the Company in the same form in which they appeared in the financial statement of the acquired entity. The differences, if any, between the consideration and the amount of share capital of the acquired entity is transferred to capital reserve (if credit) or revenue reserves (if debit) and if there are no reserves or inadequate reserves, to an amalgamation deficit reserve (if debit), with disclosure of its nature and purpose in the notes to the financial statements.

**(e) Property, plant and equipment (PPE) and intangible assets**

**(i) Property, plant and equipment**

Freehold land is carried at cost. All other items of property, plant and equipment are stated at cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment loss. The cost of an item of property, plant and equipment comprises its purchase price, including import duties and other non-refundable taxes or levies, freight, any directly attributable cost of bringing the asset to its working condition for its intended use and estimated cost of dismantling and restoring onsite; any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Advances paid towards acquisition of property, plant and equipment outstanding at each Balance Sheet date, are shown under other non-current assets and cost of assets not ready for intended use before the year end, are shown as capital work-in-progress.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

**Transition to Ind AS**

The cost of property, plant and equipment at 1 April 2015, the Company's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

**(ii) Goodwill and other intangible assets**

- For measurement of goodwill that arises from business combination, refer to accounting policy thereon above. Subsequent measurement is at cost less any accumulated impairment losses.
- Internally generated goodwill is not recognised as an asset. With regard to other internally generated intangible assets:
  - Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the Statement of Profit and Loss as incurred.
  - Development expenditure including regulatory cost and legal expenses leading to product registration/ market authorisation relating to the new and/or improved product and/or process development is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and directly attributable finance costs (in the same manner as in the case of Property, plant and equipment). Other development expenditure is recognised in the Statement of Profit and Loss as incurred.
- Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is recognised at fair value at the date of acquisition. An intangible asset is recognised only if it is probable that future economic benefits attributable to the asset will flow to the Company and the cost of the asset can be measured reliably. Following initial recognition, other intangible assets, including those acquired by the Group in a business combination and have finite useful lives are measured at cost less cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates and the cost of the asset can be measured reliably.

**Transition to Ind AS**

- The cost of Intangible assets at 1 April 2015, the Company's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

**(iii) Depreciation and amortization methods, estimated useful lives and residual value**

Depreciation is provided on straight line basis on the original cost/ acquisition cost of assets less their estimated residual values for cost of Property, plant and equipment as per the useful life specified in Part 'C' of Schedule II of the Act, read with notification dated 29 August 2014 of the Ministry of Corporate Affairs, except for certain classes of Property, plant and equipment which are depreciated based on the internal technical assessment of the management.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

The details of useful life are as under:

Category of assets	Management's estimate of useful life	Useful life as per Schedule II
Plant and Machinery		
- Laboratory equipment- Pathology	13 years	13 years
- Laboratory equipment- Imaging	10 years	13 years
Building – RCC Frame structure	60 years	60 years
Office equipment	5 years	5 years
Furniture and fittings	10 years	10 years
Furniture and fittings- signage	5 years	10 years
Vehicles	4-8 years	8 years
Computers and accessories	3 years	3 years
Air conditioners	8 years	5 years

Freehold land is not depreciated.

Depreciation on leasehold improvements is provided over the lease term or 5 years (which is the expected useful life), whichever is shorter.

Goodwill is not amortized and is tested for impairment annually or more frequently if events or changes in circumstances indicate that they might be impaired.

Estimated useful lives of the intangible assets are as follows:

Category of assets	Management's estimate of Useful Life
Software	3 years
Assay developed	5 years
Trademark and Non-Compete	5-10 years

Depreciation and amortization on property, plant and equipment and intangible assets added/ disposed off during the year has been provided on pro-rata basis with reference to the date of addition/ disposal.

Depreciation and amortization methods, useful lives and residual values are reviewed at the end of each reporting period and adjusted if appropriate.

**(iv) Derecognition**

Property, plant and equipment and intangible assets are derecognised on disposal or when no future economic benefits are expected from its use and disposal. Losses arising from retirement and gains or losses arising from disposal of a tangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss.

**(f) Impairment of non-financial assets**

Goodwill and other intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

might be impaired. The Company's non-financial assets other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows (i.e. corporate assets) are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs. Goodwill is allocated to cash-generating units for the purpose of impairment testing. The allocation is made to those cash-generating units or groups of cash-generating units that are expected to benefit from the business combination in which the goodwill arose. The units or groups of units are identified at the lowest level at which goodwill is monitored for internal management purposes.

The recoverable amount of a CGU is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment loss recognized in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amount of the other assets of the CGU (or group of CGUs) on a pro rata basis.

An impairment loss in respect of goodwill is not subsequently reversed. In respect of other assets for which impairment loss has been recognized in prior periods, the Company reviews at reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

**(g) Financial instrument**

A Financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

*Financial assets*

*Initial recognition and measurement*

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

All financial assets (except trade receivable without a significant financing component) are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

*Subsequent measurement*

For purposes of subsequent measurement, financial assets are classified as measured at:

- Amortised cost
- Fair value through other comprehensive income (FVOCI)
- Fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVOCI)

*Financial assets at amortised cost*

A 'Financial asset' is measured at the amortised cost if the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to the gross carrying amount of the financial asset or the amortised cost of the financial liability. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in other income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss. This category generally applies to trade and other receivables.

*Financial assets at FVOCI*

A 'Financial asset' is classified as at the FVOCI if the objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and the asset's contractual cash flows represent SPPI.

Financial assets included within the FVOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognised in the other comprehensive income (OCI). On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified to the Statement of Profit and Loss. Interest earned whilst holding FVOCI financial asset is reported as interest income using the EIR method.

*Financial assets at FVTPL*

FVTPL is a residual category for financial assets. Any financial asset, which does not meet the criteria for categorisation as at amortised cost or as FVOCI, is classified as at FVTPL. In addition, at initial recognition, the Company may irrevocably elect to designate a financial asset, which otherwise meets amortised cost or FVOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch').

Financial assets included within the FVTPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

*Equity investments*

Equity investments in subsidiaries and jointly controlled entities are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in such entities, the difference between net disposal proceeds and the carrying amounts are recognized in the Statement of Profit and Loss.

All other equity investments which are in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS 103 applies are classified as at FVTPL. For all other equity instruments in scope of Ind AS 109, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to the Statement of Profit and Loss, even on sale of investment. However, the Company may transfer the cumulative gain or loss to retained earnings. This decision is made on an investment-by-investment basis.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

*Impairment of financial assets*

The Company recognizes loss allowance using the expected credit loss (ECL) model for the financial assets which are not fair valued through profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all financial assets with contractual cash flows other than trade receivable, ECLs are measured at an amount equal to the 12-month ECL, unless there has been a significant increase in credit risk from initial recognition in which case those are measured at lifetime ECL. The amount of ECL (or reversal) that is required to adjust the loss allowance at the reporting date is recognised as an impairment gain or loss in the Statement of Profit and Loss.

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is recognised in OCI.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

*Write off of financial assets*

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. The Company expects no significant recovery from the amount written off.

However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

*Derecognition of financial assets*

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

*Financial liabilities*

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in Statement of Profit and Loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in Statement of Profit and Loss. Any gain or loss on derecognition is also recognised in Statement of Profit and Loss.

*Derecognition of financial liabilities*

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

*Offsetting*

Financial assets and financial liabilities are offset and the net amount presented in the Balance Sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

**(h) Inventories**

Inventories are valued at lower of cost and net realisable value except scrap, which is valued at net estimated realisable value.

The Company uses weighted average method to determine cost for all categories of inventories. Cost includes all costs of purchase, and other costs incurred in bringing the inventories to their present location and condition inclusive of non-refundable (adjustable) taxes wherever applicable.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-item basis.

**(i) Cash and cash equivalents**

Cash and cash equivalents include cash in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.

For the purpose of statement of cash flows, cash and cash equivalent includes cash in hand, in banks, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less, net of outstanding bank overdrafts that are repayable on demand and are considered part of the cash management system.

**(j) Contingent liabilities and contingent assets**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the standalone financial statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent asset is not recognised in consolidated financial statements since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

**(k) Provisions**

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate. If it is no longer probable that the outflow of resources would be required to settle the obligation, the provision is reversed.

**(l) Revenue recognition**

Revenue primarily comprises medical testing charges. Medical testing charges consists of fees received for various tests conducted in the field of pathology and radiology.

Contracts with customers could include promises to transfer multiple services to a customer. The Company assesses the services promised in a contract and identifies distinct performance obligation in the contract. Revenue for each distinct performance obligation is measured at an amount that reflects the consideration which the Company expects to receive in exchange for those services and is net of tax collected from customers and remitted to government authorities and applicable discounts and allowances including claims.

Revenue from Medical tests is recognized when the reports are generated, net of discounts, if any.

Revenue is measured based on the consideration specified in a contract with a customer. Revenue is recognised at a point in time when the Company satisfies performance obligations by transferring the promised services to its customers. Generally, each test represents a separate performance obligation for which revenue is recognised when the test report is generated i.e. when the performance obligation is satisfied. For allocating the transaction price, the Company has measured the revenue in respect of each performance obligation of a contract at its relative standalone selling price. The price that is regularly charged for a test when registered separately is the best evidence of its standalone selling price. Any revenue transaction for which the Company has acted as an agent without assuming the risks and rewards of ownership have been reported on a net basis.

Excess of revenue recognised over billings on contracts is recorded in books as unbilled revenue. Unbilled revenue is classified as trade receivables when there is unconditional right to receive cash, and only passage

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

of time is required, as per contractual terms. Contract liabilities include deferred revenue. Deferred revenue is recognised as other current liability when there is billings in excess of revenue.

Loyalty program liability represents the liability of the Company towards the points earned by the members, which entitle customers to discount on future purchase of services. The Company allocates a portion of the consideration received to loyalty points. The Company estimates the fair value of points awarded under the loyalty program by applying statistical techniques. Inputs to the model include making assumptions about expected redemption rate basis the Company's historic trends of redemption and expiry period of the points. The amount allocated to the loyalty programme is deferred and is recognised as revenue when loyalty points are redeemed or the likelihood of the customer redeeming the loyalty points becomes remote.

Other operating revenue comprises management fees which is recognised over time, in accordance with the terms of the relevant agreements, as and when services are rendered.

**(m) Employee benefits**

*Short-term employee benefits*

All employee benefits falling due within twelve months of the end of the period in which the employees render the related services are classified as short-term employee benefits, which include benefits like salaries, wages, short term compensated absences, performance incentives, etc. and are recognised as expenses in the period in which the employee renders the related service and measured accordingly.

*Post-employment benefits*

Post-employment benefit plans are classified into defined benefits plans and defined contribution plans as under:

- a) **Gratuity:**  
The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount based on the respective employee's salary and the tenure of employment. The liability in respect of gratuity is recognised in the books of account based on actuarial valuation by an independent actuary.
- b) **Provident fund:**
  - (i) The Company's contribution to provident fund is treated as defined contribution plan under which an entity pays fixed contributions to government administered fund and will have no legal or constructive obligation to pay further amounts.
  - (ii) The Company's contribution to the provident fund is charged to Statement of Profit and Loss in the periods during which the related services are rendered by employees.

*Other long-term employee benefits:*

As per the Company's policy, eligible leaves can be accumulated by the employees and carried forward to future periods to either be utilised during the service or encashed. Encashment can be made on retirement including early retirement, on withdrawal of scheme, at resignation and upon death of the employee. Accumulated compensated absences are treated as other long-term employee benefits.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

Termination benefits are recognised as an expense when, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

*Actuarial valuation*

The liability in respect of all defined benefit plans and other long-term benefits is accrued in the books of account on the basis of actuarial valuation carried out by an independent actuary using the Projected Unit Credit Method. The obligation is measured at the present value of estimated future cash flows. The discount rates used for determining the present value of obligation under defined benefit plans, is based on the market yields on Government securities as at the Balance Sheet date, having maturity periods approximating to the terms of related obligations.

Remeasurement gains and losses on other long-term benefits are recognised in the Statement of Profit and Loss in the year in which they arise. Remeasurement gains and losses in respect of all defined benefit plans arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income. They are recognised immediately in the Statement of Changes in Equity with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost. Gains or losses on the curtailment or settlement of any defined benefit plan are recognised when the curtailment or settlement occurs. Any differential between the plan assets (for a funded defined benefit plan) and the defined benefit obligation as per actuarial valuation is recognised as a liability if it is a deficit or as an asset if it is a surplus (to the extent of the lower of present value of any economic benefits available in the form of refunds from the plan or reduction in future contribution to the plan).

Past service cost is recognised as an expense in the Statement of Profit or Loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits are already vested immediately following the introduction of, or changes to, a defined benefit plan, the past service cost is recognised immediately in the Statement of Profit and Loss. Past service cost may be either positive (where benefits are introduced or improved) or negative (where existing benefits are reduced). Net interest expense is recognised as finance cost, and other expenses related to defined benefit plans are recognised as employee benefit expenses, in the statement of profit and loss.

**(n) Share-based payments**

The grant date fair value of options granted (net of estimated forfeiture) to employees of the Company is recognized as an employee benefits expense, and those granted to employees of subsidiaries is considered as the Company's equity contribution and is added to the carrying value of investment in the respective subsidiaries, with a corresponding increase in equity over the period that the employees become unconditionally entitled to the options. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share-based payment transaction is presented as a separate component in equity under "share option outstanding account". The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest. For the option awards, grant date fair value is determined under the option-pricing model (Black-Scholes-Merton). Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures materially differ from those estimates.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

**(o) Finance costs**

Finance costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Interest on lease liability is also considered as finance cost. Finance cost also includes exchange differences to the extent regarded as an adjustment to the finance costs. General and specific borrowing costs that are directly attributable to the construction or production or development of a qualifying asset are capitalized as part of the cost of that asset. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. All other finance costs are expensed in the period in which they occur.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the finance costs eligible for capitalization. Ancillary costs incurred in connection with the arrangement of borrowings are amortised over the period of such borrowings.

**(p) Income tax**

Income tax expense comprises current and deferred tax. It is recognised in Statement of Profit and Loss except to the extent that it relates to a business combination, or items recognised directly in equity or in OCI.

*Current taxes*

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received after considering uncertainty related to income taxes, if any. It is measured using tax rates enacted or substantively enacted at the reporting date.

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

*Deferred taxes*

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognised for:

- temporary differences arising on the initial recognition of assets or liabilities in a transaction that:
  - is not a business combination; and
  - at the time of transaction (i) affects neither accounting nor taxable profit or loss and (ii) does not give rise to equal taxable and deductible temporary differences
- temporary differences related to investments in subsidiaries, or joint ventures, to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and
- taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Future taxable profits are determined based on the reversal of relevant taxable temporary

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

differences. If the amount of taxable temporary differences is insufficient to recognise a deferred tax asset in full, then future taxable profits, adjusted for reversals of existing temporary differences, are considered, based on the business plans of the Company. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Deferred tax is measured at the tax rates that are expected to be applied to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

**(q) Leases**

**(i) As a lessee**

The Company accounts for assets taken under lease arrangement in the following manner:

The Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentive received.

The right of use asset is subsequently depreciated using the straight line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise the fixed payments, including in-substance fixed payments.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option or if there is a revised in-substance fixed lease payment.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

Short-term leases and leases of low-value assets

The Company has elected not to recognise right-of use assets and lease liabilities for short term leases that have a lease term of 12 months or less and leases of low value assets. The Company recognises the lease payments associated with these leases as an expense on a straight- line basis over the lease term.

**(ii) As a lessor**

The Company accounts for assets given under lease arrangement in the following manner:

Leases in which a significant portion of the risks and rewards of ownership are not transferred to the Company as lessee are classified as operating leases. Assets subject to operating leases are included in Property, Plant and Equipment. Rental income on operating lease is recognized in the Statement of Profit and Loss on a straight-line basis over the lease term. Costs, including depreciation, are recognized as an expense in the Statement of Profit and Loss. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased assets and recognised on a straight line basis over the lease term.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Company to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

**(r) Foreign currency translation**

*Transactions and balances*

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at balance sheet date exchange rates are generally recognised in Statement of Profit and Loss.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example translation differences on non-monetary assets such as equity investments classified as FVOCI are recognised in other comprehensive income (OCI).

**(s) Statement of cash flows**

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

**(t) Operating segments**

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components, and for which discrete financial information is available. Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

Maker ("CODM") who is responsible for allocating resources and assessing performance of the operating segments. Revenues, expenses, assets and liabilities, which are common to the enterprise as a whole and are not allocable to segments on a reasonable basis, have been treated as "unallocated revenues/ expenses/ assets/ liabilities", as the case may be.

**(u) Earnings per share**

(i) *Basic earnings per share*

Basic earnings per share is calculated by dividing:

- the profit attributable to owners of the Company
- by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year.

(ii) *Diluted earnings per share*

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- the after income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity share.

**(v) Recognition of Dividend Income, Interest income or expense**

Dividend income is recognised in profit or loss on the date on which the Company's right to receive payment is established.

Interest income or expense is recognised using the effective interest method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to the gross carrying amount of the financial asset; or the amortised cost of the financial liability.

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability. However, for financial assets that have become credit-impaired subsequent to initial recognition, interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit-impaired, then the calculation of interest income reverts to the gross basis.

**Note 3A. Critical estimates and judgments**

The preparation of standalone financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

**AGILUS DIAGNOSTICS LIMITED (FORMERLY KNOWN AS SRL LIMITED)**  
**NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED**  
**31 MARCH 2025**

---

### **Judgments**

Information about judgements made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes:

- Leasing arrangement (classification) – Note 2(q) and Note 39
- Revenue recognition: whether the Company acts as an agent rather than as a principal in a transaction - Note 2(l)
- Revenue Recognition (loyalty points): The Company determined that the loyalty points provide a material right that the customer would not receive without entering into the contract. The free services the customer would receive by exercising the loyalty points reflect the stand-alone selling price that a customer without an existing relationship with the Company would pay for those services. The customers right also accumulates as they purchase additional services.

### **Assumptions and estimation uncertainties**

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ending 31 March 2025 is included in the following notes:

- Financial instruments - Note 2(g)
- Fair value measurement – Note 2(c) and Note 44B
- Impairment test of goodwill and other intangible assets: key assumptions underlying recoverable amounts – Note 2(f) and Note 5
- Measurement of ECL allowance for trade receivables and other assets – Note 2(g)
- Assessment of useful life and residual value of property, plant and equipment and intangible assets – Note 2(e)
- Revenue recognition – estimate of provision for loyalty points - Note 2(l)
- Leasing arrangement (accounting) – Note 2(q) and Note 39
- Estimation of assets and obligations relating to employee benefits (including actuarial assumptions) – Note 42.
- Recognition and measurement of provisions and contingencies: key assumptions about the likelihood and magnitude of an outflow of resources – Note 41
- Recognition of deferred tax assets- Note 2(p) and Note 9.

### **Note 3B. Recent Pronouncements**

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2025, MCA has notified Ind AS – 117 Insurance Contracts and amendments to Ind AS 116 – Leases, relating to sale and leaseback transactions, applicable to the Company w.e.f. April 1, 2024. The Company has reviewed the new pronouncements and based on its evaluation has determined that it does not have any significant impact in its standalone financial statements.

**AGILUS DIAGNOSTICS LIMITED (Formerly Known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**4. Property, plant and equipment and Capital work in progress**

	Buildings	Freehold land*	Leasehold improvements	Laboratory equipment	Air conditioners	Computers and accessories	Office equipment	Furniture and fittings	Vehicles**	(Rupees in Lakhs)	
										Total	Capital work in progress
<b>Gross carrying value</b>											
<b>At 01 April 2023</b>	<b>4,248.35</b>	<b>12,082.45</b>	<b>4,396.17</b>	<b>8,923.31</b>	<b>937.30</b>	<b>2,492.75</b>	<b>712.78</b>	<b>551.96</b>	<b>478.47</b>	<b>34,823.54</b>	<b>386.97</b>
Acquisitions through business combinations (Refer note 6(A) to 4(D))	-	-	-	269.76	8.24	15.65	15.64	10.63	1.69	321.61	-
Additions	-	-	776.19	389.29	199.10	212.42	75.44	6.10	314.89	1,973.43	358.74
Disposals	-	-	67.14	260.28	12.45	40.36	31.04	3.47	52.19	466.93	710.10
<b>At 31 March 2024</b>	<b>4,248.35</b>	<b>12,082.45</b>	<b>5,105.22</b>	<b>9,322.08</b>	<b>1,132.19</b>	<b>2,680.46</b>	<b>772.82</b>	<b>565.22</b>	<b>742.86</b>	<b>36,651.65</b>	<b>35.61</b>
Additions	128.22	-	983.50	509.59	330.57	190.55	54.40	1.31	46.24	2,784.38	1,993.75
Disposals	-	-	353.40	162.95	22.36	60.23	18.20	5.49	166.68	789.31	1,277.84
<b>At 31 March 2025</b>	<b>4,376.57</b>	<b>12,082.45</b>	<b>5,735.32</b>	<b>9,668.72</b>	<b>1,440.40</b>	<b>2,810.78</b>	<b>809.02</b>	<b>561.04</b>	<b>622.42</b>	<b>38,106.72</b>	<b>351.52</b>
<b>Accumulated depreciation and impairment</b>											
<b>At 01 April 2023</b>	<b>1,184.21</b>	<b>-</b>	<b>2,975.80</b>	<b>3,612.78</b>	<b>577.69</b>	<b>1,803.82</b>	<b>496.67</b>	<b>484.29</b>	<b>180.15</b>	<b>11,315.41</b>	<b>273.06</b>
Charge for the year	71.74	-	544.53	717.61	78.30	345.69	70.66	15.90	140.13	1,984.56	-
Disposals	-	-	62.30	231.53	11.12	36.41	28.86	3.07	24.30	397.59	273.06
<b>At 31 March 2024</b>	<b>1,255.95</b>	<b>-</b>	<b>3,458.03</b>	<b>4,098.86</b>	<b>644.87</b>	<b>2,113.10</b>	<b>538.47</b>	<b>497.12</b>	<b>295.98</b>	<b>12,902.38</b>	<b>-</b>
Charge for the year	89.39	-	652.19	845.84	138.21	290.30	70.00	8.81	134.03	2,228.77	-
Disposals	-	-	352.02	153.80	20.92	53.73	14.73	4.79	109.16	709.15	-
<b>At 31 March 2025</b>	<b>1,345.34</b>	<b>-</b>	<b>3,758.20</b>	<b>4,790.90</b>	<b>762.16</b>	<b>2,349.67</b>	<b>593.74</b>	<b>501.14</b>	<b>320.85</b>	<b>14,422.00</b>	<b>-</b>
<b>Net carrying amount</b>											
<b>At 31 March 2024</b>	<b>2,992.40</b>	<b>12,082.45</b>	<b>1,647.19</b>	<b>5,223.22</b>	<b>487.32</b>	<b>567.36</b>	<b>234.35</b>	<b>68.10</b>	<b>446.88</b>	<b>23,749.27</b>	<b>35.61</b>
<b>At 31 March 2025</b>	<b>3,031.23</b>	<b>12,082.45</b>	<b>1,977.12</b>	<b>4,877.82</b>	<b>678.24</b>	<b>461.11</b>	<b>215.28</b>	<b>59.90</b>	<b>301.57</b>	<b>23,684.72</b>	<b>351.52</b>

**Notes:**

\* During the current year, the Company have closed its operations at certain laboratories. Accordingly, an accelerated depreciation of Rs. 63.53 Lakhs (Previous year Rs. 39.89 Lakhs) was charged during the year on assets relating to these locations.

\* For details regarding the title deed of immovable property of the Company (Refer note 6)

\*\* Refer to Note 20 (Non current borrowings) for disclosure of assets held as security.

Refer to Note 44(C) for information on movable property, plant and equipment pledged as security by the Company

**Capital work in progress (CWIP) ageing:-**

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Projects in progress</b>					
March 2023	351.52	-	-	-	<b>351.52</b>
March 2024	20.18	-	13.48	1.95	<b>35.61</b>
<b>Projects temporarily suspended</b>					
March 2023	-	-	-	-	-
March 2024	-	-	-	-	-

There are no projects where completion is overdue or has exceeded its cost compared to its original plan.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**5. Goodwill and Other intangible assets**

	Goodwill	Other intangible assets			(Rupees in Lakhs)
		Software	Trademark & Non compete fees	Intangible assets - Assay developed	Total other intangible assets
<b>Gross carrying value</b>					
<b>At 01 April 2023</b>	<b>1,873.25</b>	<b>2,615.11</b>	<b>364.60</b>	<b>957.68</b>	<b>3,937.39</b>
Acquisition through business combination (Refer note 46A to 46D)	7,361.25	2.77	900.30	-	903.07
Additions	-	204.92	-	-	204.92
Disposals	-	-	-	-	-
<b>At 31 March 2024</b>	<b>9,234.50</b>	<b>2,822.80</b>	<b>1,264.90</b>	<b>957.68</b>	<b>5,045.38</b>
Additions	-	29.88	-	-	29.88
Disposals	-	1.31	-	-	1.31
<b>At 31 March 2025</b>	<b>9,234.50</b>	<b>2,851.37</b>	<b>1,264.90</b>	<b>957.68</b>	<b>5,073.95</b>
<b>Accumulated amortisation</b>					
<b>At 01 April 2023</b>	-	<b>2,507.11</b>	<b>39.61</b>	<b>957.68</b>	<b>3,504.40</b>
Amortisation	-	110.96	161.26	-	272.22
Disposals	-	-	-	-	-
<b>At 31 March 2024</b>	-	<b>2,618.07</b>	<b>200.87</b>	<b>957.68</b>	<b>3,776.62</b>
Amortisation	-	109.29	188.53	-	297.82
Disposals	-	1.31	-	-	1.31
<b>At 31 March 2025</b>	-	<b>2,726.05</b>	<b>389.40</b>	<b>957.68</b>	<b>4,073.13</b>
<b>Net carrying amount</b>					
<b>At 31 March 2024</b>	<b>9,234.50</b>	<b>204.73</b>	<b>1,064.03</b>	-	<b>1,268.76</b>
<b>At 31 March 2025</b>	<b>9,234.50</b>	<b>125.32</b>	<b>875.50</b>	-	<b>1,000.82</b>

**Notes:-**

Goodwill includes the excess consideration paid by Agilus Diagnostics Limited (formerly known as SRL Limited) on the net assets of lab acquired by it.

Goodwill is tested for impairment annually at the year-end or more frequently if there are indications that goodwill might be impaired. The Company considers the whole diagnostic business of Agilus Diagnostics Limited (formerly known as SRL Limited) as a single CGU and hence, the impairment of goodwill acquired is tested on total diagnostic business of Agilus Diagnostics Limited (formerly known as SRL Limited).

The recoverable amounts of the CGUs are determined from value-in-use calculations. The key assumptions for the value-in-use calculations are those regarding the discount rates, growth rates and expected changes to selling prices and direct costs during the year. Management estimates discount rates that reflect current market assessments of the time value of money and the risks specific to the CGUs. The growth rates are based on industry growth forecasts. Changes in selling prices and direct costs are based on past practices and expectations of future changes in the market.

The Company made an assessment of recoverable amount of the CGU based on value-in-use calculations (Level -3 Fair value) which uses cash flow projections based on financial budget approved by management covering a five-year period. Cash flows beyond the five-year period were extrapolated using estimate rates stated below.

**Key Assumptions used for value in use calculations are as follows:**

Particulars	As at 31 March 2025	As at 31 March 2024
Revenue growth rate for five years (31st March 2024: 5 years)	9%-11% p.a.	2%-9% p.a.
Growth rate used for extrapolation of cash flow projections beyond five year period (31st March 2024: 5 years)	5%	5%
Discount rate (Pre tax rate)	15.2%	16%

Management believes that any reasonable possible change in any of these assumptions would not cause the carrying amount to exceed its recoverable amount.

**Revenue growth rates** - Average annual sales growth rate over the five year forecast period is based on past performance, current industry trend, management expectation of market development (including long term inflation forecast).

**Discount rates** - Management estimates discount rates that reflect current market assessments of the risks specific to the CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Company and its operating segments and is derived from its weighted average cost of capital (WACC).

**Growth rates** - The growth rates are based on industry growth forecasts. Management determines the budgeted growth rates based on past performance and its expectations of market development. The weighted average growth rates used were consistent with industry reports.

Cashflow projections during the forecast period are based on expected gross margins and inflation throughout the period.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	As at 31 March 2025 (Rupees in Lakhs)	As at 31 March 2024 (Rupees in Lakhs)
<b>6. Investments</b>		
<b>Investments at cost</b>		
Investments in Equity instruments		
<b>a) In subsidiaries</b>		
Unquoted		
3,958,200 (31 March 2024: 3,958,200) equity shares of Rs. 10 each fully-paid up in Agilus Pathlabs Private Limited (Formerly known as SRL Diagnostics Private Limited)	38,974.41	38,974.41
8,000,000 (31 March 2024: 8,000,000) equity shares of Rs. 10 each fully paid up in Agilus Pathlabs Reach Limited (Formerly known as SRL Reach Limited)	800.00	800.00
Less : Impairment in value of investment in Agilus Pathlabs Reach Limited	(800.00)	(800.00)
1,471 (31 March 2024: 1,471) equity shares of AED 1000 each fully-paid up in Agilus Diagnostics FZ LLC (Formerly known as SRL Diagnostics FZ-LLC)	3,514.46	3,514.46
Less : Impairment in value of investment in Agilus Diagnostics FZ LLC	(3,514.46)	(3,514.46)
250,000 (31 March 2024: 250,000) equity shares of Rs. 10 each, fully paid up in DDRC Agilus Pathlabs Limited (Formerly known as DDRC SRL Diagnostics Limited)	34,868.43	34,868.43
<b>Total</b>	<b>73,842.84</b>	<b>73,842.84</b>
<b>Deemed investments in subsidiary - at cost, unquoted</b>		
Agilus Pathlabs Private Limited (Formerly known as SRL Diagnostics Private Limited)#	<b>4,677.77</b>	<b>4,677.77</b>
<b>Total investment in subsidiaries</b>	<b>78,520.61</b>	<b>78,520.61</b>
#In the earlier years, the Company had paid Rs. 4,630.50 lakhs on behalf of Agilus Pathlabs Private Limited (APPL). As there is no agreed repayment period with the subsidiary, the same was disclosed as deemed investment in the financial statements. It also includes financial guarantee given on behalf of APPL for cash credit facility taken from bank and employee stock options issued to employees of APPL.		
<b>b) In joint venture</b>		
Unquoted		
240,000 (31 March 2024: 240,000) equity shares of Nepalese Rupees 100 each fully paid-up in Agilus Diagnostics Nepal Private Limited (Formely known as SRL Diagnostics (Nepal) Private Limited)	150.00	150.00
<b>Total investments in joint ventures</b>	<b>150.00</b>	<b>150.00</b>
<b>Total</b>	<b>78,670.61</b>	<b>78,670.61</b>
<b>Aggregate amount of unquoted investments</b>	<b>82,985.07</b>	<b>82,985.07</b>
<b>Aggregate amount of impairment in value of investments</b>	<b>4,314.46</b>	<b>4,314.46</b>
Information about the Company's exposure to credit and market risks, and fair value measurement is included in Note 44 (C).		
<b>7. Loans</b>		
<b>Non-current</b>		
(Unsecured considered good unless otherwise stated)		
Loans to subsidiaries*		
Considered good	8,200.00	9,700.00
Credit impaired	248.40	248.40
Less : Loss allowance	(248.40)	(248.40)
<b>Total</b>	<b>8,200.00</b>	<b>9,700.00</b>
*Loans are given for meeting working capital requirement to :		
<b>Agilus Pathlabs Private Limited</b>		
(a) Loan outstanding	Rs. 8,200 lakhs	Rs. 8,200 lakhs
Interest rate (p.a.)	10.50%	10.50%
Repayment term	Repayable on demand after 31 March 2026.	Rs. 1,000 Lakhs is repayable on demand before 31 March 2025 and balance amount is repayable on demand after 31 March 2025.
(b) Loan outstanding	Rs. 2,500 lakhs	Rs. 2,500 lakhs
Interest rate (p.a.)	10.50%	10.50%
Repayment term	Repayable by 31 December 2025	Repayable by 31 December 2025
<b>Agilus Diagnostics FZ LLC</b>		
Loan outstanding	Rs. 248.40 lakhs	Rs. 248.40 lakhs
Interest rate (p.a.)	10.50%	10.50%
Repayment term	Repayment on or before 15 December 2026	Repayment on or before 15 December 2026

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

Loans or advances in the nature of loans that are repayable on demand	As at 31 March 2025		As at 31 March 2024	
	(Rupees in Lakhs)		(Rupees in Lakhs)	
Type of Borrower	Amount of loan outstanding	% of total Loans	Amount of loan outstanding	% of total Loans
Loan to Related parties	8,200.00	75%	7,200.00	66%
<b>Total</b>	<b>8,200.00</b>	<b>75%</b>	<b>7,200.00</b>	<b>66%</b>

The Company has not granted any loans or advances in the nature of loans to promoters, directors and KMPs (as defined under Companies Act, 2013) either severally or jointly with any other person that are repayable on demand or without specifying any terms or period of repayment.

**8. Other financial assets**

**Non-current**

*(Unsecured considered good unless otherwise stated)*

Security deposits	888.20	738.82
Balances with banks		
- held as margin money*	242.53	208.25
<b>Total</b>	<b>1,130.73</b>	<b>947.07</b>

\*This includes interest accrued of Rs. 8.10 lakhs (Rs. 7.53 lakhs in previous year).

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>As at 31 March 2025 (Rupees in Lakhs)</b>	<b>As at 31 March 2024 (Rupees in Lakhs)</b>
<b>9. Deferred tax balances</b>		
Deferred tax assets	6,278.51	5,737.03
Deferred tax liabilities	(2,225.53)	(1,988.18)
<b>Deferred tax assets (net)</b>	<b>4,052.98</b>	<b>3,748.85</b>

The following is the component wise breakup of deferred tax assets/ (liabilities) presented in the financial statements:

**2024-25**

	<b>As at 1 April 2024</b>	<b>Recognised in profit or loss</b>	<b>Business combination</b>	<b>Recognised in other comprehensive income</b>	<b>As at 31 March 2025</b>
<b>Deferred tax asset</b>					
Property, plant and equipment and other intangible assets	604.03	9.33	-	-	613.36
Loss allowance for deposits and advances	83.62	(14.79)	-	-	68.83
Loss allowance for trade receivables	2,043.18	292.05	-	-	2,335.23
Lease liability	2,147.50	297.63	-	-	2,445.13
Provision for gratuity	479.76	8.14	-	15.14	503.04
Provision for compensated absences	221.89	(4.81)	-	-	217.08
Expenditure allowed on actual payment basis	94.54	(61.21)	-	-	33.33
Loss allowance for loans	62.51	-	-	-	62.51
<b>Total deferred tax assets</b>	<b>5,737.03</b>	<b>526.34</b>	<b>-</b>	<b>15.14</b>	<b>6,278.51</b>
<b>Deferred tax liability</b>					
Right-of-use assets	(1,988.18)	(237.35)	-	-	(2,225.53)
<b>Total deferred tax liability</b>	<b>(1,988.18)</b>	<b>(237.35)</b>	<b>-</b>	<b>-</b>	<b>(2,225.53)</b>
<b>Deferred tax asset (net)</b>	<b>3,748.85</b>	<b>288.99</b>	<b>-</b>	<b>15.14</b>	<b>4,052.98</b>

**2023-24**

	<b>As at 1 April 2023</b>	<b>Recognised in profit or loss</b>	<b>Business combination (refer note 46A to 46D)</b>	<b>Recognised in other comprehensive income</b>	<b>As at 31 March 2024</b>
<b>Deferred tax asset</b>					
Property, plant and equipment and other intangible assets	693.22	(89.19)	-	-	604.03
Loss allowance for deposits and advances	128.87	(45.25)	-	-	83.62
Loss allowance for trade receivables	1,579.94	463.24	-	-	2,043.18
Lease liability	1,278.04	673.55	195.91	-	2,147.50
Provision for gratuity	428.81	43.62	-	7.33	479.76
Provision for compensated absences	200.85	21.04	-	-	221.89
Expenditure allowed on actual payment basis	55.52	39.02	-	-	94.54
Loss allowance for loans	75.11	(12.60)	-	-	62.51
<b>Total deferred tax assets</b>	<b>4,440.36</b>	<b>1,093.43</b>	<b>195.91</b>	<b>7.33</b>	<b>5,737.03</b>
<b>Deferred tax liability</b>					
Right-of-use assets	(1,179.30)	(612.97)	(195.91)	-	(1,988.18)
<b>Total deferred tax liability</b>	<b>(1,179.30)</b>	<b>(612.97)</b>	<b>(195.91)</b>	<b>-</b>	<b>(1,988.18)</b>
<b>Deferred tax asset (net)</b>	<b>3,261.06</b>	<b>480.46</b>	<b>-</b>	<b>7.33</b>	<b>3,748.85</b>

Deferred tax asset has not been recognized on temporary differences in relation to investment in subsidiaries and joint venture as the Company is able to control the timing of the reversal of the temporary difference and it is probable that the temporary differences will not reverse in foreseeable future.

**10. Other tax assets (net)**

Advance tax and tax deducted at source*	3,083.32	5,042.99
<b>Total</b>	<b>3,083.32</b>	<b>5,042.99</b>
*Net of provision for tax	36,647.01	35,675.96

**11. Other non-current assets**

(Unsecured considered good unless otherwise stated)

Capital advances		
- Considered good	182.18	523.32
Advances other than capital advances		
- Prepaid expenses	5.35	5.06
- Deposit against cases with income tax authorities	92.17	66.64
<b>Total</b>	<b>279.70</b>	<b>595.02</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	As at 31 March 2025 (Rupees in Lakhs)	As at 31 March 2024 (Rupees in Lakhs)
<b>12. Inventories</b>		
(lower of cost and net realisable value)		
Consumables : Reagents, chemicals and others	2,868.33	2,858.45
<b>Total</b>	<b>2,868.33</b>	<b>2,858.45</b>
<b>13. Trade receivables</b>		
Secured, considered good	368.03	573.61
Unsecured, considered good	9,071.12	9,485.94
Unsecured, credit impaired	6,511.67	4,522.47
Less: Allowance for expected credit loss	(8,329.66)	(7,169.34)
	<b>7,621.16</b>	<b>7,412.68</b>
Dues from related parties (refer note 38)		
Unsecured, considered good	5,550.47	4,491.26
Unsecured, credit impaired	948.19	948.19
Less: Allowance for expected credit loss	(948.19)	(948.19)
	<b>5,550.47</b>	<b>4,491.26</b>
<b>Total</b>	<b>13,171.63</b>	<b>11,903.94</b>
Gross Trade Receivables	22,449.48	20,021.47
Less: Allowance for expected credit loss	(9,277.85)	(8,117.53)
<b>Net Trade Receivables</b>	<b>13,171.63</b>	<b>11,903.94</b>
<b>Trade receivables ageing</b>		
<b>Outstanding for following periods from due date of payment</b>		
<b>Undisputed trade receivables- considered good</b>		
Not Due	8,574.39	6,569.29
Less than 6 months	3,772.67	3,412.64
6 months-1 year	934.35	1,257.51
1-2 years	1,122.18	1,518.57
2-3 years	477.50	1,444.44
More than 3 years	108.53	348.36
<b>Total (A)</b>	<b>14,989.62</b>	<b>14,550.81</b>
<b>Undisputed trade receivable- Credit impaired</b>		
Not Due	-	46.07
Less than 6 Months	0.06	718.49
6 Months-1 year	121.17	923.69
1-2 Yrs	0.58	-
2-3 Yrs	337.55	-
More than 3 Years	3,738.69	2,543.50
<b>Total (B)</b>	<b>4,198.05</b>	<b>4,231.75</b>
<b>Disputed trade receivables- credit impaired</b>		
Not Due	0.94	0.06
Less than 6 months	133.66	0.16
6 months-1 year	464.08	19.71
1-2 years	1,153.61	62.27
2-3 years	92.38	69.08
More than 3 years	1,417.14	1,087.63
<b>Total (C)</b>	<b>3,261.81</b>	<b>1,238.91</b>
<b>Total (A+B+C)</b>	<b>22,449.48</b>	<b>20,021.47</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**Notes:-**

- (a) Credit risk arising from trade receivables is managed in accordance with the Company's established policy with regard to credit limits, control and approval procedures. The concentration of credit risk is limited due to the fact that the customer base is large. The Company further limits its credit risk by establishing a maximum credit period of upto 180 days for all its customers (other than related parties). There are no customers which represent more than 5% of the total balance of trade receivables except as mentioned below:

**Customer Name**

	<b>As at 31 March 2025 (Rupees in Lakhs)</b>	<b>As at 31 March 2024 (Rupees in Lakhs)</b>
Fortis Hospitals Limited	2,663.83	1,960.91
Agilus Diagnostics FZ LLC	1,450.27	1,557.60

- (b) In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss towards expected risk of delays and default in collection. The Company has used a practical expedient by computing the expected credit loss allowance based on a provision matrix. Management makes specific provision in cases where there are known specific risks of customer default in making the payments. The provision matrix takes into account historical credit loss experience and adjusted for forward- looking information. The expected credit loss allowance is based on the ageing of the days the receivables are due and the rates as given in the provision matrix. The provision matrix at the end of the reporting period is as follows:

	<b>As at 31 March 2025 Expected credit loss (%)</b>	<b>As at 31 March 2024 Expected credit loss (%)</b>
Not Due	1% - 21%	3% - 16%
0-1 year	6% - 34%	15% - 25%
1-2 Years	29% - 76%	56% - 70%
2-3 Years	56% - 99%	61% - 89%
Above 3 Years	100%	100%

**Movement in the expected credit loss allowance**

Balance at beginning of the year	8,117.53	6,277.09
Add: Recognised during the year	1,197.24	2,635.07
Less: Bad debts written off	(36.92)	(794.63)
<b>Balance at end of the year</b>	<b>9,277.85</b>	<b>8,117.53</b>

Information about Company's exposure to credit risk and currency risk is disclosed in Note 44(C).

**14. Cash and cash equivalents**

	<b>As at 31 March 2025 (Rupees in Lakhs)</b>	<b>As at 31 March 2024 (Rupees in Lakhs)</b>
Balances with banks		
- On current accounts	442.93	2,354.12
- Deposit with original maturity of three months or less*	650.23	-
Cash on hand	54.57	54.48
<b>Total</b>	<b>1,147.73</b>	<b>2,408.60</b>

\* Includes interest accrued of Rs. 0.23 lakhs (Previous year: Rs. Nil).

**15. Bank balances other than cash and cash equivalents**

Balances with banks*		
- deposits with original maturity of more than 3 months but less than 12 months	7,087.82	3,138.14
<b>Total</b>	<b>7,087.82</b>	<b>3,138.14</b>

\* Includes interest accrued of Rs. 24.74 lakhs (Previous year: Rs. 22.73 lakhs).

**16. Loans**

**Current**

*(Unsecured considered good unless otherwise stated)*

Loan to subsidiary (refer note 7)*	3,535.26	2,069.68
<b>Total</b>	<b>3,535.26</b>	<b>2,069.68</b>

\* Includes interest accrued of Rs. 1,035.26 lakhs (Previous year: Rs. 1,069.68 lakhs).

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	As at 31 March 2025 (Rupees in Lakhs)	As at 31 March 2024 (Rupees in Lakhs)
<b>17. Other financial assets</b>		
<b>Current</b>		
<i>(Unsecured considered good unless otherwise stated)</i>		
Security deposits		
- Considered good	60.43	443.71
- Credit impaired	167.05	167.05
Less: Loss allowance	(167.05)	(167.05)
Recoverable from shareholders*	-	1,488.59
Advances recoverable		
- Considered good#	148.03	63.73
- Credit impaired	61.45	120.22
Less: Loss allowance	(61.45)	(120.22)
<b>Total</b>	<b>208.46</b>	<b>1,996.03</b>
# Includes advances to related party (refer note 38)	62.83	50.73
* Represents amount incurred by the Company in previous year in relation to Offer for sale by existing shareholders through Proposed Initial Public Offer ('IPO'). The same has been recovered in current year. Also refer note 38		
<b>18. Other current assets</b>		
<i>(Unsecured considered good unless otherwise stated)</i>		
Prepaid expenses		
- Considered good	552.72	450.53
- Considered doubtful	9.30	9.30
Less: Loss allowance	(9.30)	(9.30)
Advances to supplier and employees		
- Considered good	318.17	957.86
- Considered doubtful	35.66	35.66
Less: Loss allowance	(35.66)	(35.66)
Balance with statutory authorities	0.68	2.78
<b>Total</b>	<b>871.57</b>	<b>1,411.17</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**19. Equity share capital**

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	(Rupees in Lakhs)	Number of shares	(Rupees in Lakhs)
<b>Authorised share capital</b>				
Equity shares of Rs. 10 each	8,90,00,000	8,900.00	8,90,00,000	8,900.00
Compulsorily convertible preference shares of Rs. 20 each	40,00,000	800.00	40,00,000	800.00
<b>Total</b>	<b>9,30,00,000</b>	<b>9,700.00</b>	<b>9,30,00,000</b>	<b>9,700.00</b>
<b>Issued, subscribed and paid up share capital</b>				
Equity Shares of Rs.10 each fully paid up shares for consideration in cash	6,00,17,582	6,001.76	6,00,17,582	6,001.76
Equity Shares of Rs.10 each fully paid up shares for consideration other than cash	1,84,07,960	1,840.80	1,84,07,960	1,840.80
<b>Total</b>	<b>7,84,25,542</b>	<b>7,842.56</b>	<b>7,84,25,542</b>	<b>7,842.56</b>

**a) Reconciliation of the shares outstanding at the beginning and at the end of the year**

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	(Rupees in Lakhs)	Number of shares	(Rupees in Lakhs)
<b>Equity shares of Rs.10 each</b>				
Outstanding at the beginning of the year	7,84,25,542	7,842.56	7,84,25,542	7,842.56
Outstanding at the end of the year	<b>7,84,25,542</b>	<b>7,842.56</b>	<b>7,84,25,542</b>	<b>7,842.56</b>

**b) Terms/rights attached to equity shares**

The Company has only one class of equity shares having a par value of Rs. 10 each. In the event of liquidation of the Company, the holder of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. Each holder of equity share is entitled to one vote per share.

**c) Shares held by holding Company/ultimate holding company and/or its subsidiaries :**

Equity Shares of Rs.10 each	As at 31 March 2025			As at 31 March 2024		
	No. of shares	Rupees in lakhs	% of Total Shares	No. of shares	Rupees in lakhs	% of Total Shares
<b>Promoter's Name</b>						
Fortis Healthcare Limited	6,99,55,054	6,995.51	89.20%	4,52,36,779	4,523.68	57.68%
Fortis Healthcare Limited is the promoter of the Company.						

**d) Details of shares held by each shareholder holding more than 5% shares :**

	As at 31 March 2025		As at 31 March 2024	
	Number of Shares	% of Holding	Number of Shares	% of Holding
<b>Equity shares of Rs. 10 each</b>				
Fortis Healthcare Limited	6,99,55,054	89.20%	4,52,36,779	57.68%
Resurgence PE Investments Limited (Formerly known as Avigo PE Investments Ltd)	-	-	63,10,315	8.05%
NYLIM Jacob Ballas India Fund III LLC	-	-	1,24,37,811	15.86%
International Finance Corporation	-	-	59,70,149	7.61%
Axis Bank Limited	43,00,000	5.48%	43,00,000	5.48%

**(e) Shareholding of Promoter**

Promoter's Name	No. of shares as at 31 March 2024		Change during the year	No. of shares as at 31 March 2025		% of Total Shares as on 31 March 2025	% Change during the year
<b>Equity shares of Rs. 10 each</b>							
Fortis Healthcare Limited	4,52,36,779	2,47,18,275	6,99,55,054	89.20%	31.52%		
	<b>4,52,36,779</b>	<b>2,47,18,275</b>	<b>6,99,55,054</b>	<b>89.20%</b>	<b>31.52%</b>		
Promoter's Name	No. of shares as at 31 March 2023		Change during the year	No. of shares as at 31 March 2024		% of Total Shares as on 31 March 2024	% Change during the year
<b>Equity shares of Rs. 10 each</b>							
Fortis Healthcare Limited	4,52,36,779	-	4,52,36,779	57.68%	-		
	<b>4,52,36,779</b>	-	<b>4,52,36,779</b>	<b>57.68%</b>	-		

**f) Share options under the Company's employee share option plan**

a) Under the 'Super Religare Laboratories Limited Employee Stock Option Plan 2009' (the 'Scheme') as at 31 March 2025 - 513,209 (31 March 2024: 513,209) outstanding options are convertible into 513,209 (31 March 2024: 513,209) equity shares. (refer note 47).

b) Under the 'SRL Limited Employee Stock Option Scheme 2013' (the 'Scheme') as at 31 March 2025 - 271,500 (31 March 2024: 271,500) outstanding options are convertible into 271,500 (31 March 2024: 271,500) equity shares. (refer note 47).

**g) No shares have been allotted without payment of cash or by way of bonus shares or bought back during the period of five years immediately preceding the reporting date.**

**AGILUS DIAGNOSTICS LIMITED (Formerly Known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>20. Non - current borrowings</b>		
<b>Term loans</b>		
<b>Vehicle loans (Secured)*</b>		
From Banks	243.47	335.48
From Financial Institution	-	4.32
Less: Current maturities classified as current borrowings (Refer note 23)	(98.05)	(115.71)
Less: Interest accrued but not due on borrowings (Refer note 25)	(1.93)	(2.63)
<b>Total non-current borrowings</b>	<b>143.49</b>	<b>221.46</b>
*The Company has taken vehicle loans on the following terms:		
Rate of interest ranging from	7.50% - 9.15% p.a	7.50% - 9.15% p.a
Loan repayable in	48 monthly instalments	48 monthly instalments
The vehicle loan is secured by hypothecation of respective assets (vehicles). Information about the Company's exposure to interest rate and liquidity risks is included in Note 44(C).		
<b>21. Provisions</b>		
<b>Non-current</b>		
<b>Provision for employee benefits</b>		
Provision for gratuity (refer note 42)	1,531.99	1,548.79
Provision for compensated absences	632.55	690.57
<b>Total</b>	<b>2,164.54</b>	<b>2,239.36</b>
<b>22. Lease Liability*</b>		
- Current	1,559.85	1,613.68
- Non-Current	8,154.63	6,918.29
<b>Total</b>	<b>9,714.48</b>	<b>8,531.97</b>
*Refer note 39		
<b>23. Borrowings - current</b>		
Current maturities of non-current borrowings (Refer note 20)	98.05	115.71
<b>Total</b>	<b>98.05</b>	<b>115.71</b>
<b>24. Trade payables</b>		
(i) total outstanding dues of micro enterprises and small enterprises (MSME) (refer note 45)	2,414.14	1,570.73
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	6,076.75	6,549.40
	<b>8,490.89</b>	<b>8,120.13</b>
<b>Trade payable ageing - undisputed</b>		
<b>Outstanding for following periods from due dates of payments</b>		
<b>Micro enterprises and small enterprises (MSME) - Undisputed</b>		
Not due	780.41	1,080.84
Less than 1 year	1,375.66	468.47
1-2 years	103.94	8.41
2-3 years	48.13	8.63
More than 3 years	106.00	4.38
<b>Total (A)</b>	<b>2,414.14</b>	<b>1,570.73</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly Known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>Others - Undisputed</b>		
Not due	590.16	553.67
Less than 1 year	3,229.53	4,080.92
1-2 years	832.47	935.39
2-3 years	987.60	582.11
More than 3 years	436.99	397.31
<b>Total (B)</b>	<b>6,076.75</b>	<b>6,549.40</b>
<b>Total (A + B)</b>	<b>8,490.89</b>	<b>8,120.13</b>

Information about the Company's exposure to foreign currency and liquidity risks is included in Note 44(C). The Company does not have any disputed dues which are payable as at 31 March 2025 and 31 March 2024. Refer note 38 for related party disclosures.

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>25. Other financial liabilities</b>		
<b>Current</b>		
Deposit from customers	1,001.94	1,245.28
Employee benefits payable	1,374.94	1,354.89
Payable on purchase of property, plant and equipment#	135.64	114.34
Deferred/ contingent purchase consideration (refer note 46A to 46D)	1,799.06	3,332.50
Liability against indemnification*	74.70	74.70
Payable to related parties (refer note 38)	-	2.08
Interest accrued but not due on borrowings (refer note 20)	1.93	2.63
<b>Total</b>	<b>4,388.21</b>	<b>6,126.42</b>

# includes payable to Micro Enterprises and Small Enterprises (MSME) of Rs. 101.97 Lakhs (Previous year: Rs. 47.71 lakhs).

\*At the time of acquisition of Piramal labs (Agilus Pathlabs Private Limited), it was agreed that any charge relating to tax litigations before the date of acquisition shall be indemnified to Agilus Diagnostics Limited. Accordingly, the amount paid by Piramal to Agilus Diagnostics Limited, has been shown under liability against indemnification till tax litigations are settled.

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>26. Other current liabilities</b>		
Advances from customers *	710.14	951.15
Statutory dues payable	730.42	867.16
Liability towards customer loyalty program**	195.23	175.05
Deferred revenue (refer note 49)	80.53	86.64
<b>Total</b>	<b>1,716.32</b>	<b>2,080.00</b>
* includes advances from related party (refer note 38)	-	15.89
**The movement during the year is as below:		
Opening balance	175.05	172.41
Addition during the year	268.58	240.13
Utilised/ lapsed during the year	(248.40)	(237.49)
Closing balance	<b>195.23</b>	<b>175.05</b>

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>27. Provisions</b>		
<b>Current</b>		
<b>Provision for employee benefits</b>		
Provision for gratuity (refer note 42)	466.65	357.32
Provision for compensated absences	229.84	190.94
<b>Total</b>	<b>696.49</b>	<b>548.26</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly Known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>Year ended 31 March 2025 (Rupees in Lakhs)</b>	<b>Year ended 31 March 2024 (Rupees in Lakhs)</b>
<b>28. Revenue from operations</b>		
Sale of services (refer note 49)	84,990.44	84,673.84
Other operating revenues		
- Liabilities/provisions no longer required written back	432.65	139.39
- Management fees	407.04	1,067.65
<b>Total</b>	<b>85,830.13</b>	<b>85,880.88</b>
<b>29. Other income</b>		
Interest income earned on financial assets measured at amortised cost:		
- Bank deposits	214.87	482.18
- Loans to subsidiaries	1,149.58	1,208.32
- Security deposits	59.71	65.73
Interest income on:		
- Income tax refund	357.26	-
Gain on sale of investment	25.42	38.11
Exchange differences (net)	2.51	12.85
Gain on termination of lease	141.73	26.43
Dividend income from equity instruments in subsidiaries and joint venture	1,325.28	2,395.51
Miscellaneous income	33.00	55.30
<b>Total</b>	<b>3,309.36</b>	<b>4,284.43</b>
<b>30. Cost of materials consumed</b>		
Reagents, chemicals and consumables		
Inventories at the beginning of the year	2,858.45	4,434.76
Add: Purchase during the year (net)	21,828.07	20,579.51
	<b>24,686.52</b>	<b>25,014.27</b>
Less: Inventories at the end of the year	2,868.33	2,858.45
<b>Total</b>	<b>21,818.19</b>	<b>22,155.82</b>
<b>31. Employee benefits expense</b>		
Salaries, wages and bonus	17,805.28	18,758.62
Contribution to provident and other funds (refer note 42)	976.87	1,057.90
Gratuity expense (refer note 42)	239.07	247.44
Staff welfare expenses	205.39	259.35
<b>Total</b>	<b>19,226.61</b>	<b>20,323.31</b>
<b>32. Finance costs</b>		
Interest expense on financial liabilities measured at amortised cost:		
- borrowings	23.82	25.68
Interest expense on:		
- deferred purchase consideration	194.20	226.94
- net defined benefit obligation (refer note 42)	136.19	124.63
- lease liabilities (refer note 39)	769.88	597.49
- others	112.88	101.87
Bank charges	77.87	78.21
<b>Total</b>	<b>1,314.84</b>	<b>1,154.82</b>
<b>33. Depreciation and amortisation expense</b>		
Depreciation of property, plant and equipment	2,228.77	1,984.56
Depreciation of right-of-use assets (refer note 39)	2,056.43	1,985.18
Amortisation of intangible assets	297.82	272.22
<b>Total</b>	<b>4,583.02</b>	<b>4,241.96</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly Known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>34. Other expenses</b>		
Power and fuel	1,099.11	1,054.96
Rent and hire charges (Refer note 39)	1,060.44	1,189.02
Rates and taxes	147.77	135.66
Insurance	246.39	196.63
Repairs and maintenance:		
- Plant and machinery	1,398.62	1,278.39
- Buildings	32.53	18.07
- Others	500.09	248.03
Advertisement and sales promotion	7,438.81	5,968.62
Postage and courier	3,902.52	3,738.75
Travelling and conveyance	324.86	314.08
Printing and stationery	220.38	218.94
Communication	199.64	183.24
Fees to collection centers (refer note 2(l))	9,236.60	9,641.20
Legal and professional (refer note below for payment to auditors)	1,810.70	2,359.34
Professional fees to doctors	3,867.56	3,759.73
Loss on disposal of property, plant and equipment (net)	3.90	4.81
Loss allowance for deposits and advances	10.77	20.23
Loss allowance for trade receivables (refer note 13)	1,197.24	2,635.07
Contingent consideration for lab acquisition	1,015.11	436.96
Corporate Social Responsibility expenses (refer note 43)	198.40	266.50
Housekeeping expenses	279.28	343.35
Security services expenses	229.28	257.19
Miscellaneous expenses	235.40	356.64
<b>Total</b>	<b>34,655.40</b>	<b>34,625.41</b>

**Note: Payment to the auditors (net of tax):**

**As auditor**

Statutory audit	47.28	52.70
Tax audit	3.75	3.31
Limited review	28.50	26.78
Other services#	7.75	346.11

**In other capacity**

Reimbursement of expenses	5.68	30.78
<b>Total</b>	<b>92.96</b>	<b>459.68</b>

# Previous year amount includes audit fees amounting to Rs. 343.11 lakhs recorded as recoverable from shareholders (refer note 17).

**35. Exceptional loss\***

Loss allowance on loan to subsidiary	-	(50.00)
<b>Total</b>	<b>-</b>	<b>(50.00)</b>

\*In earlier years, owing to continuous losses along with the relevant economic and market indicators including the impact of uncertainties on achievement of future cash flow projections, the management of the Company had performed an impairment test on the carrying value of its investment and loan in Agilus Diagnostics FZ LLC, a wholly owned subsidiary company and recognised full impairment loss. During the previous year, the Company had recovered Rs. 50.00 lakhs loan given to Agilus Diagnostics FZ LLC, accordingly impairment loss to that extent had been reversed during the previous year.

**36. (a) Income taxes:**

**Recognised in profit and loss:**

Current tax expense	966.46	1,218.17
Deferred tax credit	(288.99)	(480.46)
<b>Total</b>	<b>677.47</b>	<b>737.71</b>

**Recognised in other comprehensive income :**

Tax expense/ (income) related to items that will not be reclassified to profit or loss	(15.14)	(7.33)
<b>Total</b>	<b>(15.14)</b>	<b>(7.33)</b>

**(b) Reconciliation of effective tax rate:**

	<b>Tax rate</b>	<b>Year ended 31 March 2025 (Rupees in Lakhs)</b>	<b>Tax rate</b>	<b>Year ended 31 March 2024 (Rupees in Lakhs)</b>
<b>Profit before tax</b>		3,380.18		4,655.38
Tax using Company's domestic tax rate @ 25.17%	25.17%	850.79	25.17%	1,171.76
<b>Tax effect of :</b>				
Tax exempt income	-9.87%	(333.57)	-12.64%	(588.23)
Non deductible expenses	4.74%	160.25	3.31%	154.18
<b>Income tax expense recognised in profit and loss</b>	<b>20.04%</b>	<b>677.47</b>	<b>15.85%</b>	<b>737.71</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly Known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>37. Earnings per share (EPS)</b>		
Basic earnings per share in Rupees (refer details below)	<b>3.45</b>	<b>5.00</b>
Diluted earnings per share in Rupees (refer details below)	<b>3.42</b>	<b>4.96</b>
<b>Basic earnings per share</b>		
The earnings and weighted average number of equity shares used in the calculation of basic earnings per share are as follows:		
Earnings used in the calculation of basic earning per share:		
Profit for the year attributable to owners of the Company	2,702.71	3,917.67
Weighted average number of equity shares for the purpose of basic EPS	7,84,25,542	7,84,25,542
<b>Diluted earnings per share</b>		
The earnings and weighted average number of equity shares used in the calculation of diluted earnings per share are as follows:		
Earnings used in the calculation of basic earning per share:		
Profit for the year attributable to owners of the Company	2,702.71	3,917.67
Weighted average number of equity shares for the purpose of diluted EPS	7,90,20,136	7,90,04,021
<b>Reconciliation of weighted average number of equity shares used for the purpose of diluted EPS with weighted average number of equity shares used in the calculation of basic EPS:</b>		
Weighted average number of equity shares used in the calculation of basic earnings per share	7,84,25,542	7,84,25,542
Shares deemed to be issued for no consideration in respect of:		
- Employee stock options (numbers)	5,94,594	5,78,479
Weighted average number of equity shares for the purpose of diluted EPS	<b>7,90,20,136</b>	<b>7,90,04,021</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

---

**38. Related party disclosures**

**A. Related parties where control exists :**

- (i) **Ultimate holding company**  
IHH Healthcare Berhad
- (ii) **Enterprises having direct control over the Company / Holding Company**  
Fortis Healthcare Limited, holding company
- (iii) **Subsidiaries**  
Agilus Pathlabs Private Limited (Formerly known as SRL Diagnostics Private Limited)  
Agilus Pathlabs Reach Limited (Formerly known as SRL Reach Limited)  
Agilus Diagnostics FZ LLC (Formerly known as SRL Diagnostics FZ- LLC)  
DDRC Agilus Pathlabs Limited (Formerly known as DDRC SRL Diagnostics Limited)
- (iv) **Joint venture**  
Agilus Diagnostics Nepal Private Limited (Formerly known SRL Diagnostics (Nepal) Private Limited)

**B. Other related parties with whom transactions have taken place during the current and previous year:**

**1. Enterprises owned or controlled by Holding company (Directly or Indirectly)**

Escorts Heart Institute & Research Centre Limited  
Fortis Health Management Limited  
Fortis Hospitals Limited  
Fortis Malar Hospitals Limited  
Hiranandani Healthcare Private Limited  
International Hospital Limited  
Hospitalia Eastern Private Limited  
Escorts Heart and Super Speciality Hospital Limited

**2. Enterprises owned or controlled/ significantly influenced by ultimate holding company (Directly or Indirectly)**

Centre for Digestive and Kidney Diseases (India) Private Limited  
Bharat Insecticides Limited  
Gleneagles Healthcare India Private Limited (Formerly known as Ravindranath GE Medical Associates Private Limited)

**3. Enterprise significantly influenced by holding company**

Lanka Hospitals Diagnostics (Pvt) Ltd

**4. Enterprise jointly controlled by the Holding Company**

Fortis C-DOC Healthcare Limited

**5. Enterprises having significant influence over the Company**

Resurgence PE Investments Limited (Formerly known as Avigo PE Investments Ltd) (Upto 17 January 2025)  
NYLIM Jacob Ballas India Fund III LLC (Upto 17 January 2025)

**6. Entities having a common director**

Jacob Ballas Capital India Private Limited (Upto 24 September 2023)

**C. Key Managerial Personnel**

Mr. Ravi Rajagopal, Independent Director (Upto 30 September 2024)  
Ms. Suvalaxmi Chakraborty, Independent Director  
Mr. Anand K, Managing Director & Chief Executive Officer  
Mr. Indrajeet Banerjee, Independent Director (From 01 October 2024)  
Mr. Mangesh Shrikant Shirodkar, Chief Financial Officer (Upto 07 September 2024)  
Mr. Akshay Kumar Tiwari, Chief Financial Officer (From 09 September 2024)  
Mr. Murlee Manohar Jain, Company Secretary (Upto 23 September 2023)  
Ms. Trapti, Company Secretary (From 25 September 2023 to 26 November 2024)

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**D. Transactions with related parties during the year**

	Year ended 31 March 2025 (Rupees in Lakhs)	Year ended 31 March 2024 (Rupees in Lakhs)
<b>(i) Rendering of services:</b>		
Escorts Heart Institute & Research Centre Limited	1,582.73	1,912.41
Fortis C-DOC Healthcare Limited	52.21	84.67
Fortis Health Management Limited	317.64	333.16
Fortis Healthcare Limited	1,229.27	1,710.30
Fortis Hospitals Limited	11,602.52	12,200.16
Fortis Malar Hospitals Limited	-	239.76
Hiranandani Healthcare Private Limited	242.23	326.49
Agilus Diagnostics FZ LLC	672.85	653.64
Agilus Diagnostics Nepal Private Limited	340.31	266.09
Agilus Pathlabs Private Limited	1,932.95	1,354.34
Agilus Pathlabs Reach Limited	58.33	83.88
DDRC Agilus Pathlabs Limited	704.80	520.85
International Hospital Limited	105.46	152.26
Lanka Hospitals Diagnostics (Pvt) Ltd	38.18	50.18
Hospitalia Eastern Private Limited	64.52	12.21
Gleneagles Healthcare India Private Limited	500.31	0.71
	<b>19,444.31</b>	<b>19,901.11</b>
<b>(ii) Receiving of services:</b>		
<b>(a) Cost of test outsourced</b>		
Fortis Healthcare Limited	13.59	10.57
Fortis Hospitals Limited	58.72	53.08
DDRC Agilus Pathlabs Limited	54.55	36.11
Escort Heart Institute & Research Centre Limited	-	0.67
Agilus Pathlabs Private Limited	2,882.97	1,824.45
	<b>3,009.83</b>	<b>1,924.88</b>
<b>(b) Rent Expense</b>		
Escorts Heart and Super Speciality Hospital Limited	1.68	0.98
	<b>1.68</b>	<b>0.98</b>
<b>(iii) Reimbursement of expenses to:</b>		
Fortis Healthcare Limited	-	19.88
Fortis Hospitals Limited	69.30	54.53
Agilus Pathlabs Private Limited	-	5.61
Agilus Diagnostics Nepal Private Limited	31.31	24.88
Agilus Pathlabs Reach Limited	-	0.01
DDRC Agilus Pathlabs Limited	4.26	5.55
	<b>104.87</b>	<b>110.46</b>
<b>(iv) Reimbursement of expenses from*</b>		
Fortis Hospitals Limited	0.99	0.59
Hiranandani Healthcare Private Limited	131.45	131.09
Agilus Diagnostics FZ LLC	11.80	25.67
Fortis Healthcare Limited	-	9.44
Agilus Pathlabs Reach Limited	2.75	1.03
Agilus Diagnostics Nepal Private Limited	-	0.19
Agilus Pathlabs Private Limited	0.10	0.29
	<b>147.09</b>	<b>168.30</b>

\* In addition to the above, Rs. 1,488.59 lakhs was recoverable for reimbursement of expenses jointly from Resurgence PE Investments Limited, NYLIM Jacob Ballas India Fund III LLC and International Finance Corporation as an 31 March 2024. The same has been recovered in current year.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	Year ended 31 March 2025 (Rupees in Lakhs)	Year ended 31 March 2024 (Rupees in Lakhs)
<b>(v) Repayments of loans given</b>		
Agilus Pathlabs Private Limited	-	500.00
Agilus Diagnostics FZ LLC	-	50.00
	<b>-</b>	<b>550.00</b>
<b>(va) Interest income</b>		
Agilus Pathlabs Private Limited	1,123.50	1,178.64
Agilus Diagnostics FZ LLC	26.08	29.68
	<b>1,149.58</b>	<b>1,208.32</b>
<b>(vi) Remuneration to key managerial personnel</b>		
<b>Salary and wages</b>		
Mr. Anand K, Managing Director & Chief Executive Officer	528.84	542.53
Mr. Mangesh Shrikant Shirodkar, Chief Financial Officer	81.83	186.16
Mr. Akshay Kumar Tiwari, Chief Financial Officer	66.07	-
Mr. Murlee Manohar Jain, Company Secretary	-	19.88
Mr. Ravi Rajagopal*	6.00	17.70
Ms. Suvalaxmi Chakraborty*	12.00	21.24
Ms. Trapti, Company Secretary	20.16	12.70
Mr. Indrajit Banerjee*	4.00	-
	<b>718.90</b>	<b>800.21</b>
* Sitting fees paid		
<b>(vii) Purchase of Reagents and consumables</b>		
Fortis Hospitals Limited	4.30	18.39
Agilus Pathlabs Private Limited	-	1.83
	<b>4.30</b>	<b>20.22</b>
<b>(viii) Purchase of property, plant and equipment</b>		
Agilus Pathlabs Private Limited	3.19	7.04
DDRC Agilus Pathlabs Limited	-	20.12
	<b>3.19</b>	<b>27.16</b>
<b>(ix) Sale of Reagents and consumables</b>		
DDRC Agilus Pathlabs Limited	-	1.87
Agilus Pathlabs Private Limited	0.76	-
	<b>0.76</b>	<b>1.87</b>
<b>(x) Sale of property, plant and equipment</b>		
Agilus Pathlabs Private Limited	1.95	0.37
Agilus Pathlabs Reach Limited	0.01	1.49
	<b>1.96</b>	<b>1.86</b>
<b>(xi) Reversal of loss allowance on loan</b>		
Agilus Diagnostics FZ LLC	-	50.00
	<b>-</b>	<b>50.00</b>
<b>(xii) Dividend income</b>		
DDRC Agilus Pathlabs Limited	662.68	1,168.55
Agilus Pathlabs Private Limited	662.60	1,168.46
Agilus Diagnostics Nepal Private Limited	-	58.50
	<b>1,325.28</b>	<b>2,395.51</b>
<b>(xiii) Dividend paid</b>		
Fortis Healthcare Limited	764.50	1,348.06
Resurgence PE Investments Limited	106.64	188.05
NYLIM Jacob Ballas India Fund III LLC	210.20	370.65
	<b>1,081.34</b>	<b>1,906.76</b>
<b>(xiv) Security Deposit given</b>		
Escorts Heart and Super Speciality Hospital Limited	-	0.42
	<b>-</b>	<b>0.42</b>
<b>(xv) Rent income</b>		
Agilus Pathlabs Private Limited	1.26	0.45
Agilus Pathlabs Reach Limited	1.26	0.45
	<b>2.52</b>	<b>0.90</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>As at 31 March 2025 (Rupees in Lakhs)</b>	<b>As at 31 March 2024 (Rupees in Lakhs)</b>
<b>E. Balances outstanding at the year end :</b>		
<b>(i) Loans (including interest accrued)</b>		
Agilus Pathlabs Private Limited	11,711.15	11,760.78
Agilus Diagnostics FZ LLC	272.51	257.30
	<b>11,983.66</b>	<b>12,018.08</b>
<b>(ii) Trade receivables</b>		
Escorts Heart Institute & Research Centre Limited	361.69	181.52
Fortis C-DOC Healthcare Limited	340.10	383.11
Fortis Health Management Limited	76.63	29.45
Fortis Healthcare Limited	444.95	479.36
Fortis Hospitals Limited	2,663.83	1,960.91
Hiranandani Healthcare Private Limited	92.66	31.86
Agilus Diagnostics FZ LLC	1,450.27	1,557.60
Agilus Diagnostics Nepal Private Limited	550.83	415.91
Agilus Pathlabs Reach Limited	3.10	211.95
Agilus Pathlabs Private Limited	194.87	96.37
DDRC Agilus Pathlabs Limited	112.33	48.98
International Hospital Limited	41.41	28.65
Gleneagles Healthcare India Private Limited	121.76	0.82
Hospitalia Eastern Private Limited	21.29	12.21
Bharat Insecticides Limited	0.31	0.31
Centre for Digestive and Kidney Diseases (India) Private Limited	0.12	0.44
Lanka Hospitals Diagnostics (Pvt) Ltd	22.54	-
	<b>6,498.69</b>	<b>5,439.45</b>
<b>(iii) Trade payables</b>		
Agilus Pathlabs Private Limited	606.08	399.47
Fortis Healthcare Limited	7.74	12.08
DDRC Agilus Pathlabs Limited	4.53	-
Agilus Diagnostics Nepal Private Limited	65.75	32.66
	<b>684.10</b>	<b>444.21</b>
<b>(iv) Other Financial Liabilities</b>		
Agilus Pathlabs Private Limited	-	2.08
DDRC Agilus Pathlabs Limited	0.02	-
	<b>0.02</b>	<b>2.08</b>
<b>(v) Advance from customers</b>		
Lanka Hospitals Diagnostics (Pvt) Ltd	-	15.89
	<b>-</b>	<b>15.89</b>
<b>(vi) Advances recoverable</b>		
Agilus Diagnostics FZ LLC	56.11	46.64
Agilus Pathlabs Reach Limited	2.75	0.12
Lanka Hospitals Diagnostics (Pvt) Ltd	3.97	3.97
	<b>62.83</b>	<b>50.73</b>
<b>(vii) Expected credit loss allowance- Trade receivables</b>		
Agilus Diagnostics FZ LLC	948.19	948.19
	<b>948.19</b>	<b>948.19</b>
<b>(viii) Impairment in value of investment</b>		
Agilus Pathlabs Reach Limited	800.00	800.00
Agilus Diagnostics FZ LLC	3,514.46	3,514.46
	<b>4,314.46</b>	<b>4,314.46</b>
<b>(ix) Loss allowance on loan to subsidiary</b>		
Agilus Diagnostics FZ LLC	248.40	248.40
	<b>248.40</b>	<b>248.40</b>
<b>(x) Security Deposit</b>		
Escorts Heart and Super Speciality Hospital Limited	0.42	0.42
	<b>0.42</b>	<b>0.42</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**G. Terms and conditions of transactions with related parties**

a. The sale to and purchase from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at year end are unsecured and interest free and settlement occurs in cash. This assessment is undertaken each financial year through examining the financial assumptions and the market in which the related parties operates.

**39. Leases**

**As lessee**

**Labs, Offices, Godowns and Guest houses**

The Company has obtained lab premises, office premises, godowns and guest houses on operating lease arrangements. The lease terms vary from 11 months to 11 years. There are no restrictions imposed by the lease arrangements.

<b>(i) Right-of-use assets - Buildings</b>	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>Particulars</b>		
Opening balance	8,162.66	4,864.82
Acquisitions (Refer note 46A to 46D)	-	778.44
Additions to right of use assets	4,538.97	4,692.19
Depreciation charge for the year	(2,056.43)	(1,985.18)
Derecognition of right of use assets	(1,522.10)	(187.61)
<b>Closing balance</b>	<b>9,123.10</b>	<b>8,162.66</b>
<b>Lease liabilities</b>	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>Maturity analysis - contractual undiscounted cash flows</b>		
Less than one year	2,317.76	2,230.97
One to five years	7,043.11	5,787.91
More than five years	3,245.75	2,870.99
<b>Total undiscounted lease liabilities</b>	<b>12,606.62</b>	<b>10,889.87</b>
<b>Lease Liabilities included in the Balance Sheet</b>		
Current	1,559.85	1,613.68
Non-current	8,154.63	6,918.29
	<b>9,714.48</b>	<b>8,531.97</b>
<b>(ii) Amounts recognised in profit or loss</b>	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>Expenses arising from leases:</b>		
Interest on lease liabilities	769.88	597.49
Expenses relating to short-term leases (including GST)	1,060.44	1,189.02
<b>(iii) Amounts recognised in statement of cash flows</b>	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
Total cash outflow for lease liabilities (includes interest of Rs. 769.88 Lakhs (31 March 2024: Rs. 597.49 Lakhs))	2,381.84	2,251.32
<b>As Lessor</b>	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>Operating lease</b>		
Rental income from premises subleased recognised in the standalone statement of profit and loss	13.10	12.85
	<b>13.10</b>	<b>12.85</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**40. Commitments**

	As at 31 March 2025 (Rupees in Lakhs)	As at 31 March 2024 (Rupees in Lakhs)
Commitments for the acquisition of property, plant and equipment	783.06	536.24

(a) Going concern support in form of funding and operational support letter issued by the company in favour of Agilus Pathlabs Reach Limited and Agilus Diagnostics FZ LLC.

(b) The Company has other commitments, for purchase/sales orders which are issued after considering requirements per operating cycle for purchase/sale of services, employee's benefits. The Company does not have any long term commitments or material non-cancellable contractual commitments/contracts.

**41. Contingent liabilities**

**Claims against the Company, disputed by the Company, not acknowledged as debt :**

(i)	Particulars	As at	
		31 March 2025	31 March 2024
	Income tax	6,821.74	6,874.77
	Medical related	5,386.50	5,408.15
	Others	63.35	77.73
	GST and Service tax	1,127.57	1,127.57
	<b>Total</b>	<b>13,399.16</b>	<b>13,488.22</b>

(ii) Further, refer claims assessed as contingent liability described in Note 55 to 59.

(iii) The Company had received a claim of Rs. 935.00 Lakhs from an ex-employee alleging certain dues payable by the Company to him in respect to his variable pay, provident fund and ESOPs. The ex-employee had also filed a similar claim of Rs. 1,923.04 Lakhs on the Parent company (Fortis Healthcare Limited). Subsequently, the claimant has filed a petition with National Company Law Tribunal (NCLT) and revised his claim amount to Rs. 3,637.80 Lakhs. The company has filed the response to the petition on merits submitting that the Petition is not maintainable either under facts or law. The matter is currently pending with National Company Law Tribunal.

(iv) On 28 February 2019, a judgment of the Supreme Court of India interpreting certain statutory defined contribution obligations of employees and employers (the "India Defined Contribution Obligation") altered historical understandings of such obligations, extending them to cover additional portions of the employee's income to measure obligations under employees Provident Fund Act, 1952. There are numerous interpretative issues relating to this judgement as to how the liability should be calculated, including the period of assessment, the application with respect to certain current and former employees and whether interest and penalties may be assessed. As such, the Company has been legally advised not to consider that there is any probable obligations for periods prior to date of aforesaid judgment.

Additionally, the Company is involved in other disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings, including commercial matters that arise from time to time in the ordinary course of business.

The Company believes that none of the above matters, either individually or in aggregate, are expected to have any material adverse effect on its financial statements. The cash flows in respect of above matters are determinable only on receipt of judgements/decisions pending at various stages/forums.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**42. Employee benefits plans**

**(i) Defined contribution plans**

The Company makes contribution towards employees' provident fund and employees' state insurance plan scheme on behalf of the employees. Under the schemes, the Company is required to contribute a specified percentage of payroll cost, as specified in the rules of the scheme. The Company has recognised the following amounts during the year as expense towards contribution to these plans:

	<b>Year ended 31 March 2025 (Rupees in Lakhs)</b>	<b>Year ended 31 March 2024 (Rupees in Lakhs)</b>
Provident fund	932.60	999.63
Employees' state insurance scheme	38.91	53.10
Labour welfare fund	5.36	5.17
	<b>976.87</b>	<b>1,057.90</b>

**(ii) Defined benefit plans**

**Gratuity**

The Company has a defined benefit gratuity plan, wherein every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service subject to a maximum limit of Rs. 20 lakhs in terms of the provisions of Gratuity Act, 1972. The gratuity plan is unfunded.

These plans typically expose the Company to actuarial risks such as: investment risk, interest rate risk, longevity risk and salary risk.

<b>Investment risk</b>	The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds.
<b>Interest risk</b>	A decrease in the bond interest rate will increase the plan liability; however, this will be partially offset by an increase in the return on the plan's debt instruments.
<b>Longevity risk</b>	The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
<b>Salary risk</b>	The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

The principal assumptions used for the purposes of the actuarial assumptions were as follows:

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
Discount rate	6.50% p.a.	7.15% p.a.
Expected rate of salary increase	6.50% p.a.	6.50% p.a.
Longevity (Mortality) rate	Indian Assured Lives 2012-14 Ultimate	Indian Assured Lives 2012-14 Ultimate
Employee turnover (attrition rate)		
Up to 30 years	32% p.a.	27% p.a.
31-44 years	28% p.a.	20% p.a.
Above 44 years	15% p.a.	12% p.a.

	<b>Year ended 31 March 2025 (Rupees in Lakhs)</b>	<b>Year ended 31 March 2024 (Rupees in Lakhs)</b>
<b>Net employee benefits expense</b>		
Current service cost	239.07	247.44
Total gratuity expenses included in employee benefit expenses (Note 31)	239.07	247.44
Interest cost on benefit obligation included in finance cost	136.19	124.63
<b>Recognised in statement of profit and loss</b>	<b>375.26</b>	<b>372.07</b>

**Remeasurement on the net defined benefit liability:**

- Actuarial (gain) arising from changes in demographic assumptions	(23.45)	-
- Actuarial loss arising from changes in financial assumptions	65.45	14.15
- Actuarial loss arising from experience adjustments	18.17	14.99
<b>Recognised in other comprehensive income</b>	<b>60.17</b>	<b>29.14</b>

<b>Total</b>	<b>435.43</b>	<b>401.21</b>
--------------	---------------	---------------

The current service cost and the net interest expense for the year are included in the 'Employee benefits expense' and 'Finance costs' line item respectively in the Statement of profit and loss. The remeasurement of the net defined benefit liability is included in other comprehensive income.

The amount included in the Balance Sheet arising from the entity's obligation in respect of its defined benefit plans is as follows:

	<b>As at 31 March 2025 (Rupees in Lakhs)</b>	<b>As at 31 March 2024 (Rupees in Lakhs)</b>
Present value of unfunded defined benefit obligation (Refer note 21 and 27)	1,998.64	1,906.11
	<b>1,998.64</b>	<b>1,906.11</b>

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
Movement in the present value of the defined benefit obligation are as follows:		
Opening defined benefit obligation	1,906.11	1,703.68
Current service cost	239.07	247.44
Interest cost	136.19	124.63
Re-measurement or Actuarial (gain) / loss arising from		
- Change in demographic assumptions	(23.45)	-
- Change in financial assumptions	65.45	14.15
- Experience adjustments	18.17	14.99
Benefits paid	(345.20)	(198.78)
Transfer In	2.30	-
<b>Closing defined benefit obligation</b>	<b>1,998.64</b>	<b>1,906.11</b>

Significant actuarial assumptions for the determination of the defined obligation are discount rate, expected salary increase and attrition rate. The sensitivity analysis below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
If the discount rate increases by 1%	1,918.99	1,815.47
If the discount rate decreases by 1%	2,084.79	2,005.47
If the expected salary growth increases by 1%	2,082.16	2,001.91
If the expected salary growth decreases by 1%	1,919.67	1,816.62
If attrition rate increases by 1%	1,995.29	1,905.12
If attrition rate decreases by 1%	2,002.01	1,906.88
If mortality rate increases by 1%	1,998.69	1,906.26
If mortality rate decreases by 1%	1,998.58	1,905.96

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

The weighted average duration of the defined benefit obligation as at 31 March 2025 is 4 years (31 March 2024: 5 years).

The defined benefit plans shall mature after year end as follows:

**Expected total benefits payments**

	<b>As at 31 March 2025</b>	<b>As at 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
Year 1	466.65	357.32
Year 2	393.28	315.77
Year 3	312.90	282.27
Year 4	271.22	249.89
Year 5	215.85	223.09
Next 5 years	714.07	821.53

The estimates of future salary increases, considered in actuarial valuation, take into account the inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

**Experience adjustments**

	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
Experience adjustment on plan liabilities- (gain) / loss	18.17	14.99

**43. Corporate social responsibility**

As per section 135 of the Companies Act, 2013 and the rules therein, the Company is required to spend at least 2% of the average net profit of past three years towards Corporate Social Responsibility (CSR). Details of the CSR expenses, as certified by Management, are as follows:

	<b>Year ended 31 March 2025</b>	<b>Year ended 31 March 2024</b>
	<b>(Rupees in Lakhs)</b>	<b>(Rupees in Lakhs)</b>
<b>Additional information</b>		
(i) Amount required to be spent by the Company during the year	198.40	266.50
(ii) Amount approved by the Board to be spent during the year	198.40	266.50
(iii) Amount spent during the year		
(a) Construction/ acquisition of any asset	-	-
(b) On purposes other than (a) above	198.40	266.50
(iv) Shortfall at the end of the year	-	-
(v) Total of previous years shortfall	-	-
(vi) Reason for shortfall	-	-
(vii) Nature of CSR activities	Contributed for scholarship to foundation for excellence india trust and stipend to National Apprenticeship Promotion Scheme (NAPS) Trainees.	Contributed to Yuva Unstoppable, Mamta Health Institute For Mother & Child and stipend to National Apprenticeship Promotion Scheme (NAPS) Trainees.
(viii) details of related party transactions e.g, contribution to a trust controlled by the Company in relation to CSR expenditure as per relevant accounting standard	-	-
(ix) Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown seperately.	-	-

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**44. Financial instruments**

**44A Capital Management**

The Company manages its capital to ensure that Company will be able to continue as going concern. The Company's management reviews the capital structure of the Company on periodic basis. As part of this review, the management considers the cost of capital and the risks associated with each class of capital. The Capital structure of the Company consists of net debt (borrowings as detailed in notes and offset by cash and bank balances) and total equity of the Company. The Company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants. The Company is not subject to any externally imposed capital requirements.

The Gearing ratio at end of reporting period was as follows:-

	As at 31 March 2025 (Rupees in Lakhs)	As at 31 March 2024 (Rupees in Lakhs)
Debt (i)	241.54	337.17
Cash and bank balances (Refer note 14)	1,147.73	2,408.60
Bank balances other than cash & cash equivalent (refer note 15)	7,087.82	3,138.14
<b>Net Debt/ (Surplus) (A)</b>	<b>(7,994.01)</b>	<b>(5,209.57)</b>
<b>Total equity (B)</b>	<b>1,40,290.33</b>	<b>1,38,958.04</b>
Net debt to equity ratio (A/B)	Nil	Nil

(i) Debt is defined as long-term and short-term borrowings as described in note 20 and 23.

**44B. Fair value measurement**

		Carrying value	
		As at 31 March 2025	As at 31 March 2024
<b>Financial assets</b>			
<b>Not measured at fair value</b>			
Loans - non current*	(b)	8,200.00	9,700.00
Loans - current*	(a)	3,535.26	2,069.68
Other financial assets - non current	(b)	1,130.73	947.07
Other financial assets - current	(a)	208.46	1,996.03
Trade Receivables	(a)	13,171.63	11,903.94
Cash and cash equivalents	(a)	1,147.73	2,408.60
Bank balances other than above	(a)	7,087.82	3,138.14
<b>Total</b>		<b>34,481.63</b>	<b>32,163.46</b>
<b>Financial liabilities</b>			
<b>Measured at fair value</b>			
Contingent purchase consideration	(d)	1,799.06	3,332.50
<b>Not measured at fair value</b>			
Borrowings : non - current **	(b)	143.49	221.46
Lease Liabilities - non current	(c)	8,154.63	6,918.29
Borrowings : current **	(a)	98.05	115.71
Lease Liabilities - current	(c)	1,559.85	1,613.68
Trade payables	(a)	8,490.89	8,120.13
Other financial liabilities - current	(a)	2,589.15	2,793.92
<b>Total</b>		<b>22,835.12</b>	<b>23,115.69</b>

\* Loans include interest bearing loans to subsidiaries given at market rate of interest.

\*\* Borrowings include interest bearing loans taken at market rate of interest from Banks and Financial Institutions.

The following methods / assumptions were used to estimate the fair values:

(a) Fair valuation of financial assets and liabilities with short term maturities is considered as approximate to respective carrying amount due to the short term maturities of these instruments.

(b) Fair valuation of non-current financial assets and liabilities has been disclosed to be same as carrying value as there is no significant difference between carrying value and fair value.

(c) Fair value measurement of lease liabilities is not required to be disclosed.

(d) Contingent consideration is payable on achievement of pre-determined business targets. Management has estimated that the target will be achieved basis which the agreed purchase consideration has been considered as the fair value.

(e) The above disclosure does not include investment in subsidiaries and joint venture of Rs. 78,670.61 Lakhs (Previous year Rs. 78,670.61 Lakhs) which are shown at carrying value (net of impairment) as per IND AS 27 "Separate Financial Statements".

There are no financial instruments which are valued under category Level 1, Level 2 and Level 3.

**44C Financial risk management objectives and Policies**

The Company's financial assets includes trade receivables, cash and bank balances, loans and other financial assets that are derived from its operations. The Company's principal financial liabilities comprise trade payables, other liabilities, borrowings and lease liabilities. The main purpose of these financial liabilities is to finance the Company's operations. The Company has exposure to the following risk arising from financial instruments.

- (a) Credit risk
- (b) Market risk
- (c) Liquidity risk

The Company's board of directors manages the financial risk of the Company through internal risk report which analyse exposure by magnitude of risk.

**(a) Credit risk**  
**(i) Trade receivable**

Credit risk is the risk of financial loss to the Company if a customer or counter party to a financial instrument fails to meet its contractual obligation and arises principally for the Company's receivable from customers. An impairment analysis is performed at each reporting date on an individual basis for major customers. The Company holds certain amounts as collateral in form of security deposits against certain class of receivables (primarily includes receivable from collection center).

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. Also, management considers the factors that may influence the credit risk of its customer base, including the default risk associated with the individual characteristics of the customers.

Credit risk is managed through credit approvals and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business. Credit period is established for each customer. Any overdue beyond credit period is monitored by Company.

In monitoring customer credit risk, customers are grouped according to their credit characteristics, including whether they are a direct client, collection center, franchisee, government agency, history of business with the Company and existence of previous financial difficulties.

Refer note 13 for a summary of company's most significant customers and details on impairment losses on financial assets recognised in the profit or loss.

**(ii) Current Investments**

Company limits its exposure to credit risk by generally investing in liquid securities. Further, defined limits are in place for exposure to individual counterparties in case of mutual fund schemes.

**(iii) Loans and Other financial assets**

Loans and other financial assets mainly consists of intercompany loan, loan to employees, security deposits, advances recoverable (employee advances) and bank deposits. Bank deposits are held with banks with good credit ratings and the company does not expect any losses. The security deposit pertains to rent deposit given to lessors. The Company does not expect any losses from the non performance of these counterparties, hence no provision has been considered on balances other than those mentioned below.

The movement in the provision recognised against the above assets which are credit impaired as at the year-end is as follows:

Particulars	Amount (Rupees in Lakhs)
<b>As at 31 March 2023</b>	<b>(773.66)</b>
Written off during the year	208.22
Provision created	(20.23)
Provision reversed	50.00
<b>As at 31 March 2024</b>	<b>(535.67)</b>
Written off during the year	69.54
Provision created	(10.77)
Provision reversed	-
<b>As at 31 March 2025</b>	<b>(476.90)</b>

The Company's maximum exposure to credit risk for each of the above categories of financial assets is the carrying values at the reporting date.

**(b) Market risk**

Market risk is the risk of loss of future earnings, risk of loss due to change in interest rates, fair values or future cash flows that may result from a change in the price of financial instrument. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates and other market changes that affect market risk sensitive instruments.

Market risk includes:

- (i) Foreign currency risk
- (ii) Interest rate risk
- (iii) Other price risk

**(i) Foreign currency risk**

The Company has limited exposure in respect to foreign currency risk due to limited international operations. The Company has not taken any derivative contracts to hedge the exposure. Exchange rate exposures are managed within approved policy parameters.

The carrying amounts of the company's foreign currency denominated monetary assets and monetary liabilities at the end of the reporting year are as follows:

	Currency	As at 31 March 2025			As at 31 March 2024		
		Rupees in Lakhs	Conversion rate	Amount in foreign currency (Lakhs)	Rupees in Lakhs	Conversion rate	Amount in foreign currency (Lakhs)
Trade receivables	USD	1,395.50	85.53	16.32	715.46	83.34	8.58
Cash balances	AED	-	-	-	0.01	22.69	0.00
	EURO*	0.01	92.60	0.00	0.01	89.94	0.00
	SGD*	0.13	63.55	0.00	0.22	61.67	0.00
	USD	0.72	85.53	0.01	1.25	83.34	0.02
	BDT	0.05	0.71	0.07	0.05	0.75	0.07
	KES	0.02	0.66	0.03	-	-	-

\* Amount in foreign currency not presented due to rounding off.

**Foreign currency sensitivity**

The following table details the Company's sensitivity to a 10% increase and decrease in the Rupees against the relevant foreign currencies. 10% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 10% change in foreign currency rates. A positive number below indicates an increase in profit or equity where the Rupees strengthens 10% against the relevant currency. For a 10% weakening of the Rupee against the relevant currency, there would be a comparable impact on the profit or equity and the balances below would be negative.

Currency	2024-25		2023-24	
	10% increase	10% decrease	10% increase	10% decrease
<b>Trade Receivable</b>				
USD	139.55	(139.55)	71.55	(71.55)
<b>Impact on profit/(loss) for the year</b>	<b>139.55</b>	<b>(139.55)</b>	<b>71.55</b>	<b>(71.55)</b>
Less: Tax impact	(35.12)	35.12	(18.01)	18.01
<b>Impact on total equity</b>	<b>104.43</b>	<b>(104.43)</b>	<b>53.54</b>	<b>(53.54)</b>

Sensitivity analysis of cash balances is not given as amounts are not material.

The sensitivity analysis is unrepresentative of the inherent foreign exchange risk because the exposure at the end of the reporting period does not reflect the exposure during the year.

**(ii) Interest rate risk**

The Company is not exposed to interest rate risk because the Company does not borrow funds at floating interest rates. As on 31 March 2025, the Company has given loans to subsidiaries at fixed interest rate. Change in interest rate risk will not have a material impact on the Company's financial statements in relation to fair value of financial instruments.

**(iii) Other price risk**

The Company's investments are in the group companies and are held for strategic purposes rather than for trading purpose.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**(c) Liquidity Risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligation associated with its financial liabilities that are settled by delivering cash. The Company's ultimate responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework of the company's short-term, medium-term and long-term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. Note given below sets out details of additional undrawn facilities that the Company has at its disposal to further reduce liquidity risk.

The Company's principal sources of liquidity are cash and cash equivalent and cash flow that is generated from operations. In addition the Company has funding facilities disclosed below (secured against first pari passu charge on current assets, thereafter second pari passu charge over all moveable property, plant and equipment) which can be drawn to meet short term financial needs.

**Financial arrangement:**

The Company has access to the following undrawn borrowing facilities at the end of the reporting period:

Particulars	As at 31 March 2025		As at 31 March 2024	
	(Rupees in lakhs)		(Rupees in lakhs)	
	Sanctioned limit	Limit utilised	Sanctioned limit	Limit utilised
Cash credit facility	5,109.04	-	5,116.45	-
Letter of credit	75.00	-	75.00	-
Bank guarantee	340.96	146.46	338.55	144.05
	<b>5,525.00</b>	<b>146.46</b>	<b>5,530.00</b>	<b>144.05</b>

The following tables detail the Company's remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the company can be required to pay.

As at 31 March 2025	Contractual cash flows			(Rupees in Lakhs)
	0-1 year	Beyond 1 year	Total Amount	Carrying Amount
<b>Non interest bearing instruments</b>				
Lease liabilities - non current	-	10,288.86	10,288.86	8,154.63
Trade payables	8,490.89	-	8,490.89	8,490.89
Lease liabilities - current	2,317.76	-	2,317.76	1,559.85
Employee benefits payable	1,374.94	-	1,374.94	1,374.94
Payable on purchase of plant and equipment	135.64	-	135.64	135.64
Contingent purchase consideration	1,799.06	-	1,799.06	1,799.06
Liability against indemnification	74.70	-	74.70	74.70
Payable to related party	-	-	-	-
Deposit from customers	1,001.94	-	1,001.94	1,001.94
<b>Fixed interest bearing instruments</b>				
Borrowings (including interest accrued)	115.50	155.75	271.25	243.47
	<b>15,310.43</b>	<b>10,444.61</b>	<b>25,755.04</b>	<b>22,835.12</b>
<b>As at 31 March 2024</b>				
<b>Non interest bearing instruments</b>				
Lease liabilities - non current	-	8,658.90	8,658.90	6,918.29
Trade payables	8,120.13	-	8,120.13	8,120.13
Lease liabilities - current	2,230.97	-	2,230.97	1,613.68
Employee benefits payable	1,354.89	-	1,354.89	1,354.89
Payable on purchase of plant and equipment	114.34	-	114.34	114.34
Deferred / contingent purchase consideration	3,332.50	-	3,332.50	3,332.50
Liability against indemnification	74.70	-	74.70	74.70
Payable to related parties	2.08	-	2.08	2.08
Deposit from customers	1,245.28	-	1,245.28	1,245.28
<b>Fixed interest bearing instruments</b>				
Borrowings (including interest accrued)	140.34	245.34	385.68	339.80
	<b>16,615.23</b>	<b>8,904.24</b>	<b>25,519.47</b>	<b>23,115.69</b>

The Company expects to meet its obligations from operating cash flows and proceeds of maturing financial assets.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

---

**45. Details of dues to Micro and Small Enterprises as per MSMED Act, 2006**

The Ministry of Micro, Small and Medium Enterprises has issued an Office Memorandum dated 26 August 2008 which recommends that the Micro Enterprises and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Accordingly, the disclosure in respect of the amounts payable to such enterprises as at the year end has been made in the financial statements based on information received and available with the Company.

	<b>As at 31 March 2025 (Rupees in Lakhs)</b>	<b>As at 31 March 2024 (Rupees in Lakhs)</b>
The principal amount remaining unpaid as at the end of year	2,239.48	1,452.77
Interest due on above principal and remaining unpaid as at the end of the year	55.13	46.53
The amount of interest paid by the buyer in terms of section 16, of the Micro Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro Small and Medium Enterprise Development Act, 2006.	55.82	52.24
The amount of interest accrued and remaining unpaid at the end of each accounting year; and	276.63	165.67
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the Micro Small and Medium Enterprise Development Act, 2006.	-	-

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**Business combination**

- 46A.** During the previous year, effective from April 1, 2023, the Company acquired Deep Clinical Laboratories. The transaction was for a purchase consideration of Rs. 700.00 lakhs (Fair value of Rs 652.50 Lakhs). The amount shall be payable in three tranches Rs 350.00 Lakhs payable on Effective Date, Rs 175.00 Lakhs payable on the date of expiry of 6 months from the Closing date and Rs 175.00 Lakhs payable within 60 days from the expiry of one-year period from the closing date on achievement of revenue target. The transaction is accounted as business combination and based on purchase price allocation performed, a goodwill of Rs. 592.26 Lakhs was recorded.

The following table summarizes the recognised amount of assets and liabilities acquired:

Particulars	(Rupees in Lakhs)
	Fair Value
Trademark and non compete fees	56.90
Right of use assets	151.97
Property, plant and equipment	2.75
Software	0.59
Lease liability	(151.97)
<b>Net assets acquired</b>	<b>60.24</b>

**Goodwill**

Goodwill arising from acquisition has been determined as follows:

Particulars	(Rupees in Lakhs)
	Amount
Fair value of purchase consideration (including contingent consideration of Rs. 127.51 Lakhs)	652.50
Fair value of net identifiable assets	60.24
<b>Goodwill</b>	<b>592.26</b>

**Property, plant and equipment**

Cost approach has been adopted to estimate the fair value of Property, plant and equipment.

**Non compete**

The intangible asset related to non-compete has been valued using with or without method, which is form of the income approach. Non compete is having useful life of 10 years.

- 46B.** During the previous year, effective from April 10, 2023, the Company acquired Lifeline Laboratores, located at Green park, New Delhi. The transaction was for a purchase consideration of Rs. 4,149.29 Lakhs (Fair value of Rs 3,500.91 Lakhs) . The amount is payable in two tranches. First tranche of Rs. 3,099.29 Lakhs has been paid during the year and second tranche of Rs 1,050.00 lakhs is payable on the final closing date on achievement on revenue target. The transaction is accounted as business combination and based on purchase price allocation performed, a goodwill of Rs. 2,996.16 lakhs was recorded.

The following table summarizes the recognised amount of assets and liabilities acquired:

Particulars	(Rupees in Lakhs)
	Fair Value
Trademark and non compete fees	387.60
Net working capital	4.00
Right of use assets	113.25
Property, plant and equipment	113.15
Lease liability	(113.25)
<b>Net assets acquired</b>	<b>504.75</b>

**Goodwill**

Goodwill arising from acquisition has been determined as follows:

Particulars	Amount
	Fair value of purchase consideration (including contingent consideration of Rs. 448.74 Lakhs)
Fair value of net identifiable assets	504.75
<b>Goodwill</b>	<b>2,996.16</b>

**Property, plant and equipment**

Cost approach has been adopted to estimate the fair value of Property, plant and equipment.

**Non compete**

The intangible asset related to non-compete has been valued using with or without method, which is form of the income approach. Non compete is having useful life of 8 years.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

- 46C.** During the previous year, effective from October 03, 2023, the Company acquired Dr. Gajendra Yadav Pathology Lab, located at Rewari, Haryana. The transaction was for a purchase consideration of Rs. 2,300.00 Lakhs (Fair value of Rs 1,675.23 Lakhs). The amount is payable in two tranches. First tranche of Rs. 1,150.00 Lakhs has been paid during the year and second tranche of Rs 1,150.00 lakhs is payable within 60 days from the expiry of the one year from the closing date on achievement of revenue target. The transaction is accounted as business combination and based on purchase price allocation performed, a goodwill of Rs. 1,445.42 lakhs was recorded.

The following table summarizes the recognised amount of assets and liabilities acquired:

<b>(Rupees in Lakhs)</b>	
<b>Particulars</b>	<b>Fair Value</b>
Trademark and non compete fees	153.50
Net working capital	5.70
Right of use assets	253.18
Property, plant and equipment	68.43
Software	2.18
Lease liability	(253.18)
<b>Net assets acquired</b>	<b>229.81</b>

**Goodwill**

Goodwill arising from acquisition has been determined as follows:

<b>Particulars</b>	<b>Amount</b>
Fair value of purchase consideration (including contingent consideration of Rs. 525.23 Lakhs)	1,675.23
Fair value of net identifiable assets	229.81
<b>Goodwill</b>	<b>1,445.42</b>

**Property, plant and equipment**

Cost approach has been adopted to estimate the fair value of Property, plant and equipment.

**Non compete**

The intangible asset related to non-compete has been valued using with or without method, which is form of the income approach. Non compete is having useful life of 10 years.

- 46D.** During the previous year, effective from November 1, 2023, the Company acquired Pathocare Pathology Lab, located at Vadodara, Gujarat. The transaction was for a purchase consideration of Rs. 3,600.00 Lakhs (Fair value of Rs 2,796.72 Lakhs) . The amount is payable in three tranches. First tranche and second tranche of Rs. 825.00 Lakhs and Rs 900.00 Lakhs has been paid during the year and third tranche of Rs 1,875.00 lakhs is payable within 60 days from the expiry of demonstration period (one year from the closing date) on achievement of EBITDA target. The transaction is accounted as business combination and based on purchase price allocation performed, a goodwill of Rs. 2,327.41 lakhs has been recorded.

The following table summarizes the recognised amount of assets and liabilities acquired:

<b>(Rupees in Lakhs)</b>	
<b>Particulars</b>	<b>Fair Value</b>
Trademark and non compete fees	302.30
Net working capital	29.73
Right of use assets	260.04
Property, plant and equipment	137.28
Lease liability	(260.04)
<b>Net assets acquired</b>	<b>469.31</b>

**Goodwill**

Goodwill arising from acquisition has been determined as follows:

<b>(Rupees in Lakhs)</b>	
<b>Particulars</b>	<b>Amount</b>
Fair value of purchase consideration (including contingent consideration of Rs. 1,071.72 Lakhs)	2,796.72
Fair value of net identifiable assets	469.31
<b>Goodwill</b>	<b>2,327.41</b>

**Property, plant and equipment**

Cost approach has been adopted to estimate the fair value of Property, plant and equipment.

**Non compete**

The intangible asset related to non-compete has been valued using with or without method, which is form of the income approach. Non compete is having useful life of 12 years.

- 46E.** Goodwill on the above acquisitions is attributable mainly to the synergies expected to be achieved by integrating the acquired businesses into the Company's existing diagnostic business. None of the goodwill recognised is deductible for income tax purposes.

For the period from the respective date of acquisition till 31 March 2024, the above businesses contributed revenue of Rs. 2,309.84 lakhs to the Company's financial statements. If the said acquisitions had occurred on 1 April 2023, the management estimates that the consolidated revenue of the Company would have been Rs. 87,051.45 lakhs. Contribution of the above businesses in the previous year's profit is not available since the books of accounts are not separately maintained.

**47. Employee Stock Option Plans**

The Company has provided share-based payment scheme to eligible employees and then directors of the Company, its subsidiary (Agilus Pathlabs Private Limited), Fortis Healthcare Limited (holding company) and RHC Holding Private Limited. The shareholders of the Company granted approval to 'Super Religare Laboratories Limited Employee Stock Option Plan 2009' and 'SRL Limited Employee Stock Option Scheme 2013'. The Company has granted these options under Equity Settlement method and there are no conditions for vesting other than continued employment with the Company. Details of these schemes are as follows :

Scheme	ESOP 2009		ESOP 2013				
	Date of Board Approval	22 August 2009	23 August 2013				
Date of Shareholder's approval	17 August 2009	20 September 2013					
Method of Settlement (Cash/Equity)	Equity	Equity					
	Grant I*	Grant II	Grant III	Grant IV	Grant V	Grant VI	Grant VII
Date of grant	22 August 2009	30 September 2013	2 November 2015	8 November 2016	22 March 2017	6 May 2017	2 Aug 2017
Number of options granted	15,17,470	2,00,000	9,95,937	75,000	1,25,000	25,000	25,000
Number of options cancelled	8,49,545	1,34,000	7,24,437	75,000	1,25,000	25,000	25,000
Number of options exercised	1,54,716	66,000	-	-	-	-	-
Number of options not yet vested	-	-	-	-	-	-	-
Number of options not yet exercised	5,13,209	-	2,71,500	-	-	-	-
Vesting Period	22 August 2009 to 21 August 2012	30 September 2016 to 30 September 2018	2 November 2018 to 1 November 2020	7 November 2019 to 7 November 2021	22 March 2020 to 22 March 2022	26 May 2020 to 26 May 2022	02 August 2020 to 02 August 2022
Exercise Period up to**	21 August 2019	29 September 2022	1 November 2022	1 November 2022	1 November 2022	1 November 2022	1 November 2022
Grant value	40	201	428	674	674	674	674

The details of activity under the Plan have been summarized below:

	As at 31 March 2025		As at 31 March 2024	
	Number of Options	Weighted Average exercise price	Number of Options	Weighted Average exercise price
Outstanding at the beginning of the year	7,84,709	174.24	7,84,709	174.24
Granted during the year	-	-	-	-
Vested during the year	-	-	-	-
Exercised during the year	-	-	-	-
Reinstated during the year	-	-	-	-
Forfeited/ Cancelled during the year	-	-	-	-
Outstanding at the end of the year	7,84,709	174.24	7,84,709	174.24
Exercisable option at the end of the year	7,84,709	174.24	7,84,709	174.24
Weighted average remaining life (years)**	-	-	-	-
Range of exercise price	40-428		40-428	

\*\* In earlier years, the Company had extended the exercise period of all outstanding options (Grant I, Grant III and Grant VII) till a future event occurs (i.e. exit of existing private equity investors or any other listing event). Further, as per the revised terms, employees due to retire or getting superannuated prospectively will also be entitled to exercise the options before the future event. During the current year, the exit of private equity investors has taken place which enable the ESOP holders to exercise their rights. The Company has extended the exercise period of all outstanding options for a period of 5 years from 19 March 2025 with the approval of the board of directors.□

There are no options granted in current year. Black-Scholes Option Pricing Model has been used for computing the weighted average fair value considering the following inputs:

Particulars	Grant II	Grant III	Grant IV- V	Grant VI- VII
Vesting Schedule	100%	100%	100%	100%
Stock Price (S)	201	428	674	674
Exercise Price (X)	201	428	674	674
Volatility (s)	17.41%	15.54%	15.54%	16.19%
Risk-free Rate	8.70%	7.63%	7.63%	6.95%
Expected Option Life (T)	5yrs	5yrs	5yrs	5yrs
Dividend Yield	1.00%	0.47%	0.47%	0.47%
<b>Option Value</b>	<b>66.32</b>	<b>135.30</b>	<b>213.00</b>	<b>202.61</b>
Exit/Attrition Rate	16.50%	16.50%	16.50%	16.50%
<b>Modified Option Value</b>	<b>55.38</b>	<b>112.98</b>	<b>177.86</b>	<b>169.18</b>

**Note:-**

\*On the date of transition to Ind AS (i.e. 1 April 2015), the Company had opted for optional exemption available under Ind AS 101 'First time adoption' to not apply Ind AS 102 'Share-based Payment' for the options fully vested (ESOP Scheme 2009) as at transition date.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**48. Operating segments**

**(a) Basis for segmentation**

The Company is engaged in the business of maintaining and managing clinical reference laboratories, to provide testing and diagnostics on human beings, in the field of both pathology and radiology. As the company's business activity primarily falls within a single operating segment i.e. pathology and radiology services, there are no disclosures required to be provided in terms of Ind AS 108 on 'Operating Segments'.

**(b) Geographical information**

The geographical information analyses the Company's revenue and non-current assets by the Company's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been presented based on the geographical location of customers and segment assets which have been presented based on the geographical location of the assets.

	<b>Year ended 31 March 2025 (Rupees in Lakhs)</b>	<b>Year ended 31 March 2024 (Rupees in Lakhs)</b>
<b>(i) Revenue</b>		
India (a)	83,072.69	82,994.06
<u>Other countries</u>		
Kenya	425.53	344.21
Maldives	1,104.65	907.28
Nigeria	111.04	70.84
Sri Lanka	68.32	65.66
Ethiopia	35.77	36.35
Kazakhstan	1.20	192.27
Others	171.24	63.17
Total other countries (b)	1,917.75	1,679.78
<b>Total (a+b)</b> (Revenue excludes other operating income and other income)	<b>84,990.44</b>	<b>84,673.84</b>
<b>(ii) Non - current assets</b>		
	<b>31 March 2025 (Rupees in Lakhs)</b>	<b>31 March 2024 (Rupees in Lakhs)</b>
India	52,912.92	53,626.25
Outside India	-	-
<b>Total</b>	<b>52,912.92</b>	<b>53,626.25</b>

Non-current assets exclude deferred tax assets, income tax assets, tax paid in protest and investments. Capital advances have been shown in India as the assets against which advances have been given shall be installed in India though they have been given to parties outside India.

**(c) Major customer**

Revenue from one customer, Fortis Hospitals Limited (fellow subsidiary) is Rs. 11,602.52 Lakhs (31 March 2024 : Rs. 12,200.16 Lakhs) which is more than 10% of the Company's total revenue.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**49. Disclosure as per Ind AS 115 - Revenue from contracts with customers**

i) Particulars	As at 31 March 2025 (Rupees in Lakhs)	As at 31 March 2024 (Rupees in Lakhs)
	<b>Trade receivables</b>	13,171.63
<b>Contract liability</b>	<b>985.90</b>	<b>1,212.84</b>
Advances from Customers	710.14	951.15
Deferred revenue	80.53	86.64
Liability towards customer loyalty program (Also refer note 26)	195.23	175.05

The amount of Rs. 549.86 lakhs included in contract liabilities at 31 March 2024 has been recognised as revenue during the year ended 31 March 2025 (31 March 2024: Rs. 736.93 lakhs).

No information is provided about remaining performance obligations at 31 March 2025 or at 31 March 2024 that have an original expected duration of one year or less, as allowed by Ind AS 115.

ii (a) **Disaggregation of revenue by Geographical region**

Revenue disaggregation by geographical region is included in segment information (Refer note 48)

ii (b) **Disaggregation of revenue by sales channel**

Particulars	Year ended 31 March 2025 (Rupees in Lakhs)	Year ended 31 March 2024 (Rupees in Lakhs)
	Owned labs	61,857.41
Collection centre	20,785.19	22,343.10
Franchisees	2,347.84	2,491.20
<b>Total</b>	<b>84,990.44</b>	<b>84,673.84</b>

ii (c) **Reconciliation of revenue from contracts with customers**

Particulars	Year ended 31 March 2025 (Rupees in Lakhs)	Year ended 31 March 2024 (Rupees in Lakhs)
	Revenue from contract with customer as per the contract price	85,010.62
<b>Adjustment made to contract price on account of:-</b>		
Customer loyalty program	(20.18)	(2.64)
Discount/Rebate		
<b>Revenue from contract with customer</b>	<b>84,990.44</b>	<b>84,673.84</b>
Other operating revenue	839.69	1,207.04
<b>Revenue from operations</b>	<b>85,830.13</b>	<b>85,880.88</b>

50. The Company has established a comprehensive system of maintenance of information and documents as required by transfer pricing legislation under section 92-92F of the Income-Tax Act, 1960. Since the law requires existence of such information and documentation to be contemporaneous in nature, the Company continuously updates its documentation for the international transactions entered into with the associated enterprises during the financial year and expects such records to be in existence latest by the due date as required under law. The Management is of the opinion that its international transactions are at arm's length so that the aforesaid legislations will not have impact on the standalone financial statements, particularly on the amount of tax expense and that of provision for taxation.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**51. Ratio Analysis**

Ratio	Numerator	Denominator	As at 31 March 2025	As at 31 March 2024	% Variance	Remarks
Current ratio (in times)	Current Assets	Current Liabilities	1.70	1.39	23%	
Debt Equity Ratio (in times)	Total Debt= Borrowings + Lease Liabilities	Shareholder's Equity	0.07	0.06	11%	
Debt Service Coverage ratio (in times)	Earnings for debt service = Net profit after taxes + Non-cash operating expenses+ Interest+ Loss on sale of PPE	Debt service = Interest & Lease Payments + Principal Repayments	3.64	4.75	-24%	
Return on Equity ratio (in %)	Net Profits after taxes – Preference Dividend	Average Shareholder's Equity	1.94%	2.88%	-33%	Decrease in return in equity ratio is due to decrease in profits in the current year.
Inventory Turnover ratio (in times)	Cost of material consumed+ Cost of tests outsourced	Average Inventory	9.07	6.91	31%	Increase in inventory turnover ratio is due to decrease in average inventory.
Trade Receivable Turnover Ratio (in times)	Net credit sales = Gross credit sales - sales return	Average Trade Receivable	5.15	5.76	-11%	
Trade Payable Turnover Ratio (in times)	Net credit purchases = Gross credit purchases - purchase return	Average Trade Payables	2.63	2.30	14%	
Net Capital Turnover Ratio (in times)	Net sales = Total sales - sales return	Working capital = Current assets – Current Liabilities	7.15	11.94	-40%	Decrease in net capital turnover ratio is due to increase in current assets as compared to previous year
Net Profit ratio (in %)	Net Profit	Net sales = Total sales - sales return	3.16%	4.57%	-31%	Decrease in net profit ratio is due to decrease in profits in the current year.
Return on Capital Employed (in %)	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability	3.30%	4.17%	-21%	

**Note:** The Company has not presented return on investment ratio, since the Company invests surplus temporary funds in short term bank deposits and the income generated is insignificant to total turnover.

**52.** During the previous year, the Company had filed Draft Red Herring Prospectus (DRHP) with Securities and Exchange Board of India (SEBI) on 29 September 2023. On 13 February 2024, the Company had withdrawn the DRHP on account of commercial considerations.

**53. Additional notes**

- (i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company does not have any transactions with companies struck off.
- (iii) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.
- (iv) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (v) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of company (Ultimate Beneficiaries) or
  - (b) provide any guarantee or security or the like to or on behalf of Ultimate Beneficiary.
- (vi) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
  - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
- (vii) The Company has not entered into any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

- (viii) The Company has used the borrowings from banks and financial institutions for the specific purpose for which it was taken.
- (ix) The Company has compiled with the number of layers prescribed under the Companies Act, 2013.
- (x) The Company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year.
- (xi) The Company has not entered into scheme of arrangement which has an accounting impact in current or previous financial year.
- (xii) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (xiii) The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013) either severally or jointly with any other person that are repayable on demand or without specifying any terms or period of repayment except loan given by Agilus Diagnostics Limited ("the holding company") to Agilus Pathlabs Private Limited ("wholly owned subsidiary") amounting to Rs. 8,200 lakhs (Previous year: Rs. 7,700 lakhs) which is repayable on demand. Refer Note 7.
- 54.** The Board of Directors, at its meeting on 16 May 2025, recommended a dividend at the rate of Rs. 2.48 per equity share on 784.26 lakh shares having face value of Rs. 10 each (fully paid up) for the financial year ended March 31, 2025. This payment is subject to the approval of shareholders in the Annual General Meeting (AGM) of the Company and if approved, would result in a net cash outflow of approximately Rs. 1,944.95 lakhs.
- For the year ended 31 March 2024, the Company paid a dividend of Rs. 1.69 per equity share on 784.26 lakh shares having face value of Rs. 10 each (fully paid up). This resulted in a cash outflow of Rs. 1,325.39 lakhs. For the year ended 31 March 2023, the Company paid a dividend of Rs. 2.98 per equity share on 784.26 lakh shares having face value of Rs. 10 each (fully paid up). This resulted in a cash outflow of Rs. 2,337.08 lakhs.

**55. Investigation initiated by the erstwhile Audit and Risk Management Committee of Fortis Healthcare Limited ("Parent Company" or "FHL")**

- (a) As disclosed in the financial statements for the years ended March 31, 2018, March 31, 2019 and March 31, 2020, during the year ended March 31 2018, there were reports in the media and enquiries from, inter alia, the stock exchanges received by the Parent Company about certain inter- corporate loans given by a wholly owned subsidiary of the Parent Company. The erstwhile Audit and Risk Management Committee of the Parent Company decided to carry out an independent investigation through an external legal firm on this matter. The terms of reference of the investigation, inter alia, comprised: (i) Inter-corporate deposits (ICDs) amounting to a total of Rupees 49,414 lakhs (principal), placed by the Parent Company's wholly-owned subsidiary, Fortis Hospitals Limited (FHSL), with three borrowing companies as on July 1, 2017; (ii) the assignment of these ICDs to a third party and the subsequent cancellation thereof as well as evaluation of legal notice received from such third party ; (iii) review of intra-group transactions for the period commencing FY 2014-15 and ending on December 31, 2017; (iv) investments made in certain overseas funds by the overseas subsidiaries of the Parent Company (i.e. Fortis Asia Healthcare Pte. Ltd, Singapore and Fortis Global Healthcare (Mauritius) Limited) ; (v) certain other transactions involving acquisition of Fortis Healthstaff Limited ("Fortis Healthstaff") from an erstwhile promoter group company of Parent company, and subsequent repayment of loan by said subsidiary to the erstwhile promoter group company of Parent company. The investigation report of which was submitted to the re-constituted Board of Parent Company in June 2018.

The investigation noted certain significant findings in relation to past transactions concerning FHL and its subsidiaries with companies whose current and/ or past promoters/ directors were known to/ connected with the erstwhile promoters of the Parent Company. All such identified transactions were provided for by the Parent Company and its respective subsidiaries in the financial statements for the year ended March 31 2018.

The investigation was subject to the limitations on the information available to the external legal firm and their qualifications and disclaimers as described in their investigation report. It did not cover all related party transactions during the period under investigation. It was observed in internal correspondence within the Parent Company that transactions with certain other entities have been referred to as related party transactions. However, no further conclusions could be drawn in this regard.

- (b) Related party relationships as required under Ind AS 24 – Related Party Disclosures and the Companies Act, 2013 were as identified by the Management taking into account the findings and limitations in the Investigation Report and the information available with the Management. In this regard, in the absence of specific declarations from the erstwhile directors on their compliance with disclosures of related parties, especially considering the substance of the relationship rather than the legal form, the related parties were identified based on the declarations by the erstwhile directors and the information available through the known shareholding pattern in the entities up to March 31, 2018. Therefore, the possibility could not have been ruled out that there may have been additional related parties whose relationship may not have been disclosed and, hence, not known to the Management. While such references could not be fully analyzed during the initial investigation, the nature of these references raised certain concerns.

In order to overcome the above, the Parent Company's Board of Directors initiated additional procedures/ enquiries of certain entities in the Fortis Group that were impacted in respect of the matters investigated by the external legal firm. Pending the additional procedures/enquiries ("Additional Procedures/ Enquiries") and since the investigation was subject to the limitations on the information available to the external legal firm and their qualifications and disclaimers as described in their investigation report, as disclosed in the audited financial statements for the years ended March 31, 2018, March 31, 2019 and March 31, 2020, certain audit qualifications were made in respect of Parent Company and its Subsidiaries (including the company's) financial statements for those financial years, as the statutory auditors were unable to comment on the nature of those matters, the provisions established thereof, or any further potential impact on the financial statements.

In order to resolve the same, the Board of the Parent Company mandated the management to undertake review of certain areas in relation to historical transactions for the period April 1, 2014 to September 30, 2018 involving additional matters by engaging independent experts with specialized forensic skills to assist with the Additional Procedures/Enquiries and provide inputs and expert advice in connection therewith. The independent experts submitted their report which was discussed and considered by the Board of the Parent Company in its meeting held on September 16, 2020.

The Board of Company and its subsidiaries noted that the Additional Procedures/Enquiries had not revealed any further instances of improper transactions which had not been expensed or provided in earlier years.

In connection with the potentially improper transactions, the Parent Company has undertaken a detailed review to assess its legal rights and has initiated necessary action.

**(iii) Key findings during the investigation by the external legal firm and during the Additional Procedures/Enquiries by independent experts**

In July 2017 a Memorandum of Understanding (MoU) was entered between Agilus Diagnostics Limited ('Agilus Diagnostics' ADL or 'Company') and a body corporate (Dignity) for lease of a office space, which were amended on different dates. The Company had paid Rs. 460 Lakhs towards security deposit and fit-outs/ interior decoration to the body corporate, which was refundable on either expiry of the term of the MoU or its earlier termination. In addition, the Company has incurred Rs. 315.20 Lakhs on the said proposed office space as capital expenditure/ advance paid, to other third party vendors. The validity of MoU was extended until 31 March, 2018.

The MoU was not extended further and the Company asked the Body Corporate to refund the amounts, due as per the MoU. The party had provided the Company with two post-dated cheques for Rs. 460 Lakhs which were banked on 13 June, 2018 by the Company, but were returned from the bank with the comment "refer to drawer". As the amounts were not received, the Company had served legal notice on 3 July 2018 under Section 138 of the Negotiable Instrument Act against the body corporate. Complaint under Negotiable Instruments Act, 1881 had been filed against Dignity, its Directors and authorized signatories" (Dignity officers) before Metropolitan Magistrate Court, Mumbai ("Hon'ble Court") in August 2018. The matter is currently, pending with Hon'ble Court for further proceeding. The Company had also initiated arbitration proceeding against the body corporate for recovery of Rs. 460 Lakhs paid towards security deposit and Rs. 304 Lakhs incurred pertaining to the office space. Vide order dated February 20, 2019 Hon'ble Delhi High Court appointed an arbitrator before whom company has filed its claim. In view of the fact that Interim Resolution Professional (IRP) was appointed by NCLT for adjudication of claim pertaining to Dignity, proceedings before Arbitrator was kept in abeyance. Further, the Company had filed their respective claims before IRP in a matter filed by one of creditors of body corporate. During the previous year, IRP adjudicated the claim of the Company as "other than operational creditors" and Rs. Nil has been adjudicated. Accordingly, the claim before the Arbitrator was disposed off.

In view of above, in previous year, the Company had written off amounts aggregating to Rs. 775.20 lakhs (Capital advances Rs 302.14 Lakhs, Security deposits of Rs. 200.00 Lakhs, Capital work in progress of Rs. 273.06 Lakhs) in these standalone financial statements. These amounts were fully provided for in earlier years.

SFIO has sought information in respect of this transaction from Parent Company and the same has been duly provided by the Parent Company. Further, a complaint has been filed by the Parent Company and Fortis Hospitals Limited (FHSL) with the EOW in November 2020 against its ex-promoters and their related entities for certain other matters, in which a reference has been made to such SFIO enquiries as well as to the Company's responses thereto and EOW is investigating the matter. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

Based on investigation carried by the external legal firm and the additional procedures/enquiries by independent experts, all identified/required adjustments/disclosures have been made in the financial statements of the Company. The Parent Company has also submitted findings of the Investigation Report of the external legal firm and the additional procedures/ enquiries by independent experts to the relevant regulatory authorities. Further, on relevant aspects, the Parent Company and Fortis Hospitals Limited (FHSL) have also filed a complaint with the EOW against the erstwhile promoters/ erstwhile promoter group companies and EOW is investigating the matter. Recovery /claim proceedings have also been initiated in the matters where action was recommended by the legal counsels. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

Therefore, with this conclusion, the initial investigation initiated by the erstwhile ARMC, which was subject to the limitations on the information available to the external legal firm and their qualifications and disclaimers has been addressed through the additional procedures/enquiries by independent experts. In addition, the reconstituted Board of the Parent Company had initiated specific improvement projects to strengthen the process and control environment. The projects included revision of authority levels, both operational and financial and oversight of the Board, review of Financial Reporting processes, assessment of secretarial documentation w.r.t compliance with regulatory requirements and systems design & control enhancement for which the assessment work was done and corrective action plans were implemented.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

Accordingly, the Board of the Parent Company had taken necessary actions in consultation with the legal counsels in this regard. The investigations in so far as these issues involving the erstwhile promoters/ erstwhile promoter group companies is concerned are still pending with the regulatory authorities. The management of the Company also believes that if any action is initiated by regulatory authorities against the Company, the same should not have a significant material impact on the Company as all items which may have financial impact have already been provided for in earlier years. The Company would fully co-operate with the regulatory authorities in this regard.

**56. Matters in relation to Regulatory Authorities**

- (a) During financial year 2017-18, the Parent Company received a communication from the Securities and Exchange Board of India (SEBI), stating that an investigation has been instituted by it in the matter of the Parent Company. In the said investigation, SEBI requisitioned from the Parent Company certain information and documents relating to short term investments of approximately Rs. 473 Crores given by a wholly owned subsidiary of the Parent Company, Fortis Hospitals Limited ("FHsL"), which had been reported in media. Subsequently, a Show-Cause Notice (SCN -1) was issued by SEBI to various entities including the Parent Company, FHsL on November 20, 2020 with certain allegations. In response, a joint representation/reply was filed by the Parent Company and FHsL on December 28, 2020 praying for quashing of the SCN on various grounds.

In the joint representation/reply, the Parent Company and FHsL have submitted that they were in fact the victims of the wrongdoings of the Erstwhile Promoters (Malvinder Mohan Singh and Shivinder Mohan Singh) of the Parent Company and that victims ought not to be punished for the acts and offences of the wrongdoers. Further, the Parent Company and FHsL have submitted that the Erstwhile Promoters controlled the affairs of the Parent Company and FHsL at the time when the acts forming the subject matter of the SCN happened. The Erstwhile Promoters are no longer associated with the Parent Company and a new promoter (i.e. NTK Venture Pte. Ltd.) has assumed control of the Parent Company with the approval of the Competition Commission of India and SEBI (which has approved the open offer process triggered by the change in control). Further, various legal actions have been initiated against the Erstwhile Promoters and several steps have been taken in order to recover the diverted amounts. As such, any adverse orders against the Parent Company and FHsL would harm their existing shareholders, employees and creditors. Oral submissions in response to the SCN were made before the SEBI, Whole Time Member on January 20, 2021, and a written synopsis of the same was filed.

On April 09, 2021, SEBI issued another Show cause notice (SCN-2) to various parties including Escorts Heart Institute and Research Centre Limited (EHIRCL), a subsidiary of the Parent Company. In the said show cause notice, with respect to EHIRCL, it has been alleged that Rupees 567 crore was lent by the Parent Company to EHIRCL in 2011, which was subsequently transferred by EHIRCL to Lowe Infra and Wellness Private Limited ("Lowe") in multiple transactions for the purchase of a land parcel. This land parcel, which was allegedly to be indirectly acquired by the Parent Company through its subsidiary EHIRCL and another entity Lowe, was then transferred to RHC Holdings Private Limited ("RHC Holdings"). It has been stated in the said Show cause notice that a structured rotation of funds was carried out to portray that the loan extended by the Parent Company for the purchase of land had been paid back with interest in the year 2011. It is alleged that the Parent Company was actually paid back by RHC Holding over a period of four years ending on July 31, 2015. In this respect, the Parent Company and FHsL funds were allegedly routed through various layers in order to camouflage the transactions, and to circumvent legal provisions with respect to related party transactions.

SEBI has passed an order dated April 19, 2022 w.r.t SCN -1 and directed the Parent Company & FHsL to pursue the measures taken to recover the amount along with the interest from erstwhile Promoters & Audit Committee of Parent Company to regularly monitor the progress of such measures and report the same to Board of Directors at regular intervals. In respect to SCN-2, SEBI passed an order dated May 18, 2022. Based on the aforesaid allegations and actions taken by the Parent Company against the erstwhile promoters and related entities, SEBI has imposed a penalty of Rs 100 lakhs, Rs 50 lakhs and Rs. 100 lakhs on Parent Company, FHsL and EHIRCL respectively. Parent Company FHsL and EHIRCL have filed an appeal against the order dated April 19, 2022 before Hon'ble Securities Appellate Tribunal, Mumbai. Appeal and the matter is currently pending adjudication.. No such notice has been received from SEBI by Company.

- (b) During year ended March 31, 2018, the Registrar of Companies (ROC) under section 206(1) of the Companies Act, 2013, inter alia, had sought information in relation to the Parent Company. All requisite information in this regard has been duly shared by the Parent Company with the ROC.
- (c) The Serious Fraud Investigation Office (SFIO) of the Ministry of Corporate Affairs, under section 217(1)(a) of the Companies Act, 2013, inter alia, initiated an investigation and sought information in relation to the Parent Company, its subsidiaries (including the Company), joint ventures and associates. The Parent Company and the Company has submitted requisite information in this regard with SFIO, as requested from time to time. The outcome of the SFIO investigation cannot be ascertained as of now keeping in view the present stage of investigation.

The Investigation Report of the external legal firm was submitted by the Parent Company to the SEBI, and SFIO on June 12, 2018. Further, the Parent Company has filed complaints in the EOW against its ex- promoters and their related entities. A copy of the report of the additional procedures/ enquiries done by the independent expert have also been submitted to SEBI and SFIO on November 10, 2020.

The Parent Company, it's subsidiaries (including the company) are co-operating with the regulators in relation to the ongoing investigations to enable them to make their determination on these matters and to undertake remedial action, as may be required, and to ensure compliance with applicable laws and regulations. As per the management and in consultation with external legal counsel it is believed that the likelihood of additional impact, if any, is low and is not expected to be material.

**57. Claims assessed as contingent liability and not provided for, unless otherwise stated**

A Civil Suit filed by a Party ("Plaintiff") before the District Court, Delhi in February 2018 against various entities including the Company (together "the defendants") has been dismissed due to non-prosecution on 24 November 2023. It was filed against the Company, Fortis Healthcare Limited ("Parent company") and other entities seeking declaration that it has implied ownership of brands "Fortis", "SRL" and "La-Femme" and for restraining the defendants from alienating, encumbering, taking adverse action w.r.t. the same. Further, in the year 2018, the Parent Company had received four notices from the abovenamed Plaintiff claiming (i) Rs. 1,800 lakhs as per notices dated May 30, 2018 and June 1, 2018 (ii) Rs. 21,582 lakhs as per notice dated June 4, 2018; and (iii) Rs. 1,962 lakhs as per notice dated June 4, 2018. All these notices were responded to by the Parent Company denying any liability whatsoever. The Learned District Court had passed an ex-parte order that any transaction done in favour of a third-party affecting interest of the Plaintiff shall be subject to orders passed in the civil suit. With the dismissal of the suit, the ex-parte order stands vacated.

A Third Party who had applied for being substituted in place of the Plaintiff, had approached the Hon'ble Delhi High Court for seeking certain interim reliefs against the Parent Company. Proceedings before Delhi High Court were withdrawn by Third Party on February 24, 2020. The Parent Company filed an application for perjury against the Third Party and other entities which is pending before the Delhi High Court. During the year ended March 31, 2022, signatories of Third Party to the Term Sheet dated December 6, 2017 ("Term Sheet") had also filed a duly affirmed affidavit before Delhi High Court stating that Term Sheet was neither signed on behalf of the Parent Company before them nor did it ever come in force.

Separately, the Third Party had also alleged rights to invest in the Parent Company. It had also alleged failure on part of the Parent Company to abide by the aforementioned Term Sheet and has claimed ownership over the brands as well.

Allegations made by the Third party have been duly responded to by the Parent Company denying (i) execution of any binding agreement with the Party and (ii) liability of any kind whatsoever.

Based on external legal advice, the Management believes that the claims are without legal basis and are not tenable and accordingly no adjustment is required in these financial statements with respect to these claims.

- 58.** The Company had entered into an agreement for a period of two years with Directorate General of Health Services - Delhi Government ('DGHS') (the 'Agreement') to conduct diagnostic tests on the patients of the Aam Aadmi Mohalla Clinics. Under the Agreement and Standard Operating Procedure for Patient Related Processes, interacting with patients and collecting samples is the sole responsibility of staff at the Aam Aadmi Mohalla Clinics.

The Company has recognised revenue of Rs. 824.21 lakhs during the year (Rs. 1,647.65 lakhs in the previous year) under the said agreement, which is less than 2% of its consolidated revenue for the respective years. As of that date, total receivables due amounts to Rs. 1,945.60 lakhs.

The Company, on 18 January 2024, received a notice from the Anti-Corruption Branch, Government of National Capital Territory of Delhi, in respect of alleged anomalies in diagnostic tests conducted in Aam Aadmi Mohalla Clinics. On 18 January 2024, the Company also received a communication from DGHS that it is undertaking thorough scrutiny and verification following which the balance payments, if found rightfully due, would be released.

On 10 May 2024 and 24 September 2024, the Company also received notices from Central Bureau of Investigation (CBI), Anti-Corruption Branch, New Delhi asking for certain documents/information to investigate the above matter. The Company has submitted the requested information.

The Company vide various communications to DGHS has stated that it has duly performed its obligations under the said Agreement for the samples collected and requested for immediate release of the outstanding amounts. The Company had also filed a writ petition before Hon'ble Delhi High Court on 3rd August 2024 seeking directions for payment of admitted outstanding in relation to the pathology services provided to DGHS, Delhi. In response to the same, DGHS has filed a counter affidavit to the writ petition alleging that the Company has not met its obligations under the Agreement. The Company is in process of filing rejoinder affidavit to the same. The matter is currently pending.

Subsequently on 8 October 2024, DGHS assured the Company that:

- All undisputed bills w.e.f. March 2024 onwards will be cleared within a week's time and all prospective bills shall be cleared in a timebound manner.
- Undisputed bills of the period from February 2023 to February 2024 will be released basis recommendations of the committee constituted by DGHS.

During the year, the Company received payment of Rs. 566.70 lakhs from DGHS in respect to sales invoices raised of Rs. 870.28 lakhs subsequent to February 2024.

The period of contract had expired on 31 January 2025. However, on various written request by DGHS, the Company had extended the period of services from time to time till 23 May 2025.

Considering the delays in recovering the outstanding amounts (for the period February 2023 to February 2024), the Company has fully provided for them and recognised an impairment loss of Rs. 1,660.57 lakhs as at 31 March 2025.

The Company has been fully co-operating with the respective authorities in connection with the aforesaid notices and has been providing documents and information as sought by them. Pending completion of the proceedings, the ultimate outcome of the matter and its consequential impact, if any, is currently not ascertainable.

- 59.** During the previous year, the Company, its subsidiaries and joint venture have transitioned to a new brand 'Agilus' from 'SRL'. In connection with the said brand transition, it is relevant to highlight that the non-exclusive Brand License Agreement of the Company with the brand owner had expired on May 09, 2021. In May 2023, an application was filed in pending proceedings before Hon'ble High Court of Delhi, for restraining the Company, Agilus Pathlabs Private Limited ('Agilus Pathlabs') & Fortis Healthcare Limited ('Parent Company' or 'FHL') from abruptly dumping/discontinuing the brand 'SRL' and allied trademarks, appointment of an entity for valuation and sale of the 'SRL' and allied trademarks ("Former Brand") and directing the Company and Agilus Pathlabs to deposit an appropriate amount with the Hon'ble High Court till the sale of the Former Brand. On May 26, 2023, submissions on behalf of the Company and Agilus Pathlabs were recorded that the process of brand transition had already been initiated since year 2020 and they had been moving towards brand Agilus. Vide Order dated May 26, 2023 (26 May Order) High Court directed the Company, Agilus Pathlabs, FHL and brand owner to not to act in any manner to diminish the value of the brand SRL. Certificate of incorporation was issued by Office of the Registrar of Companies, Ministry of Corporate Affairs certifying the change of name from "SRL Limited" to "Agilus Diagnostics Limited" w.e.f. May 31, 2023. On June 02, 2023, an affidavit in compliance of order dated May 26, 2023 was filed on behalf of Agilus.

On June 02, 2023, Hon'ble High Court of Delhi appointed M/s Konverj - Zeus as valuer for valuation of brand 'SRL'. In the last week of June 2023, Decree Holder filed a Contempt Petition against the Company, Agilus Pathlabs, FHL and directors/KMPs of the Company alleging that they have knowingly and willfully disobeyed the order dated May 26, 2023 passed by Hon'ble High Court of Delhi. No notice on this petition has been issued by Hon'ble Court. Affidavits have been filed by the Company and Agilus Pathlabs to support and substantiate that it is in compliance of the May 26, 2023 Order.

In September 2023, an ex-director of Headway Brands Private Limited (company which was the owner and licensor of the Former Brand) has filed an application dated September 14, 2023 before the Delhi High Court inter alia seeking payment of Rs. 36,293 lakhs as license fee and interest for use of the Former Brand, and that an inquiry be conducted into the impact of brand transition by Agilus on valuation of the Former Brand. The High Court by its order dated September 25, 2023, while issuing notice on the said application recorded the preliminary objections of the Company and Agilus Pathlabs that the application (i) is not maintainable and (ii) the Company and Agilus Pathlabs are not necessary parties to the said application. Notice of the said application has been issued by the Court to all parties named therein for submission of their respective responses/ objections. Objections have been filed by the Company.

Court appointed valuer M/s Konverj - Zeus has filed its report which has been objected to by Agilus and an affidavit, highlighting the deficiencies and illegality therein has been filed by Agilus on October 17, 2023 supported by reports of subject matter experts i.e. Ernst & Young and Osborne Partners who in their respective reports have pointed out that in preparation of report, M/s Konverj - Zeus has applied entirely incorrect and inappropriate valuation methodologies and has made reference to incorrect dates in arriving at conclusions set out in its report. The Hon'ble Delhi High Court has ordered for public auction of SRL Brand.

On 23 April 2024, Delhi High Court in its order mentioned that the Court Commissioner informed that no bid in any form was received by him, either physically or via e-mail. The auction did not take place within stipulated time. The next date of auction is yet to be notified.

Further, as per the management and in consultation with external legal counsel it is believed that the Company has a strong case on merits and the likelihood of any impact on the financial statements is not expected to be material. The matter is pending adjudication.

**AGILUS DIAGNOSTICS LIMITED (Formerly known as SRL Limited)**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**

**60. List of immovable property not held in the name of the Company**

Relevant line item in the Balance Sheet	Description of property	Gross carrying value (Rs. in lakhs)	Whether title deed holder is a promoter, director, director or relative of promoter/director or employee of promoter/director	Held in the name of	Property held since which date	Reason for not being held in the name of the company
Property, plant and equipment - Freehold Land	Subplot A of Plot no.1 bearing CTS No. 908 A admeasuring 1,078.10 sq. mtrs. situated in Village Pahadi, Goregaon West and CTNS No. 1395 A admeasuring 800.60 sq. mtrs. bearing Survey No. 52, Hissa No. 1 and Survey No. 53 (Part) situated in Village, Malad	12,082.45	No	SRL Limited	26 Mach 2013	The deed of conveyance of freehold land is in the name of SRL Limited, erstwhile name of the Company which was changed to Agilus Diagnostics Limited on 31 May 2023.  Fresh certificate of incorporation consequent upon change of name dated 31 May 2023 was issued by the Registrar of Companies, Chandigarh.

For **B S R & Co. LLP**  
Chartered Accountants  
ICAI Firm's Registration No.:101248W/W-100022

**RAHUL NAYAR** Digitally signed by RAHUL NAYAR  
Date: 2025.05.16 23:30:40 +05'30'

**Rahul Nayar**  
Partner  
Membership Number: 508605

Place : Gurugram  
Date : 16 May 2025

For and on behalf of the Board Of Directors

**Agilus Diagnostics Limited**  
(Formerly known as SRL Limited)

**ASHUTOSH RAGHUVANSHI** Digitally signed by ASHUTOSH RAGHUVANSHI  
Date: 2025.05.16 21:48:48 +05'30'

**Dr. Ashutosh Raghuvanshi**  
Director  
DIN:02775637

**AKSHAY KUMAR TIWARI** Digitally signed by AKSHAY KUMAR TIWARI  
Date: 2025.05.16 21:36:12 +05'30'

**Akshay Kumar Tiwari**  
Chief Financial Officer

Place : Gurugram  
Date : 16 May 2025

**ANAND KUPPUSWAMY** Digitally signed by ANAND KUPPUSWAMY  
Date: 2025.05.16 21:35:30 +05'30'

**Anand K**  
Managing Director & Chief Executive Officer  
DIN:02427196

**SATYENDRA CHAUHAN** Digitally signed by SATYENDRA CHAUHAN  
Date: 2025.05.16 21:37:58 +05'30'

**Satyendra Chauhan**  
Company Secretary  
Membership No. A14783